Scholars@Duke
Keith Michael Sullivan

Keith Michael Sullivan

James B. Wyngaarden Distinguished Professor Emeritus of Medicine
Medicine, Hematologic Malignancies and Cellular Therapy
sulli025@mc.duke.edu
Box 3961 Med Ctr, Durham, NC 27710
Cellular Therapy ABMT, Box 3961 DUMC, Durham, NC 27705

Selected Publications

Toward a Cure for Autoimmune Diseases.

Journal Article Transplant Cell Ther · October 2024 Full text Link to item Cite

Myeloablation Followed by Hematopoietic Stem Cell Transplantation and Long-Term Normalization of Systemic Sclerosis Molecular Signatures.

Conference Arthritis Rheumatol · August 2024 OBJECTIVE: In the randomized Scleroderma: Cyclophosphamide or Transplantation (SCOT) trial, myeloablation, followed by hematopoietic stem cell transplantation (HSCT), led to the normalization of systemic sclerosis (SSc) peripheral blood cell (PBC) gene exp ... Full text Link to item Cite

A Year of Monthly Reflections

Journal Article Transplantation and Cellular Therapy · July 1, 2024 Full text Cite

Improving outcomes in scleroderma: recent progress of cell-based therapies.

Journal Article Rheumatology (Oxford) · June 1, 2023 Scleroderma is a rare, potentially fatal, clinically heterogeneous, systemic autoimmune connective tissue disorder that is characterized by progressive fibrosis of the skin and visceral organs, vasculopathy and immune dysregulation. The more severe form of ... Full text Link to item Cite

Characterising the autoantibody repertoire in systemic sclerosis following myeloablative haematopoietic stem cell transplantation.

Journal Article Ann Rheum Dis · May 2023 OBJECTIVES: Results from the SCOT (Scleroderma: Cyclophosphamide Or Transplantation) clinical trial demonstrated significant benefits of haematopoietic stem cell transplant (HSCT) versus cyclophosphamide (CTX) in patients with systemic sclerosis. The objec ... Full text Link to item Cite

Adjuvanted recombinant zoster vaccine decreases herpes zoster-associated pain and the use of pain medication across 3 randomized, placebo-controlled trials.

Journal Article Pain · April 2023 AbstractHerpes zoster (HZ) and HZ-associated pain greatly affect patients' quality of life, particularly in older and immunocompromised adults, for whom comorbidities and polypharmacy are often reported. Three phase III, randomized, placebo-contro ... Full text Cite

Enrollment Lessons from a Biological Assignment Study of Marrow Transplantation versus Standard Care for Adolescents and Young Adults with Sickle Cell Disease: Considerations for Future Gene and Cellular Therapy Trials.

Journal Article Transplant Cell Ther · April 2023 We previously conducted a single-arm feasibility study (STRIDE1) of myeloablative bone marrow transplantation (BMT) in adolescents and young adults with sickle cell disease (SCD). The trial identified donors before entry, enrolled well, and found no unexpe ... Full text Link to item Cite

Myeloablative autologous haematopoietic stem cell transplantation resets the B cell repertoire to a more naïve state in patients with systemic sclerosis.

Journal Article Ann Rheum Dis · March 2023 OBJECTIVES: Myeloablative autologous haematopoietic stem cell transplant (HSCT) was recently demonstrated to provide significant benefit over cyclophosphamide (CYC) in the treatment of diffuse cutaneous systemic sclerosis (dcSSc) in the Scleroderma: Cyclop ... Full text Link to item Cite

Clinical and Molecular Findings After Autologous Stem Cell Transplantation or Cyclophosphamide for Scleroderma: Handling Missing Longitudinal Data.

Journal Article Arthritis Care Res (Hoboken) · February 2023 OBJECTIVE: Among individuals with systemic sclerosis (SSc) randomized to cyclophosphamide (CYC) (n = 34) or hematopoietic stem cell transplantation (HSCT) (n = 33), we examined longitudinal trends of clinical, pulmonary function, and quality of life measur ... Full text Link to item Cite

Safety and efficacy of recombinant and live herpes zoster vaccines for prevention in at-risk adults with chronic diseases and immunocompromising conditions.

Journal Article Vaccine · January 4, 2023 Compared with the general population, older adults with immune senescence and individuals who are immunocompromised (IC) due to disease or immunosuppressive therapy are at increased risk for herpes zoster (HZ) and its associated complications, which can be ... Full text Link to item Cite

Lymphocyte subset abnormalities in early severe scleroderma favor a Th2 phenotype and are not altered by prior immunosuppressive therapy.

Journal Article Rheumatology (Oxford) · October 6, 2022 OBJECTIVES: The Scleroderma: Cyclophosphamide or Transplantation (SCOT) trial compared hematopoietic stem cell transplant to CYC treatment in patients with early SSc with progressive skin and lung or kidney involvement. Here we describe lymphocyte phenotyp ... Full text Link to item Cite

AB1072 HERPES ZOSTER IN INDIVIDUALS WITH AUTOIMMUNE DISEASES AND RECOMBINANT HERPES ZOSTER VACCINE AS A PREVENTATIVE STRATEGY

Conference Annals of the Rheumatic Diseases · June 2022 BackgroundIndividuals with autoimmune diseases (AIDs) are particularly vulnerable to herpes zoster (HZ) and its related complications. Although the live attenuated HZ vaccine is contraindicated in many of these in ... Full text Cite

Cognitive impairment in candidates for allogeneic hematopoietic stem cell transplantation.

Conference Bone Marrow Transplant · January 2022 Hematopoietic cell transplant (HCT) is an increasingly common and curative treatment strategy to improve survival among individuals with malignant and nonmalignant diseases, with over one million HCTs having been performed worldwide. Neurocognitive dysfunc ... Full text Link to item Cite

Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice.

Journal Article Hum Vaccin Immunother · November 2, 2021 Immunocompromised individuals, particularly autologous hematopoietic stem cell transplant (auHSCT) recipients, are at high risk for herpes zoster (HZ). We provide an in-depth description of humoral and cell-mediated immune (CMI) responses by age (protocol- ... Full text Link to item Cite

Re-evaluating inclusion criteria for autologous hematopoietic stem cell transplantation in advanced systemic sclerosis: Three successful cases and review of the literature.

Journal Article J Scleroderma Relat Disord · June 2021 Systemic sclerosis is a chronic autoimmune disease with a poor prognosis, particularly when a patient has rapidly progressive skin or pulmonary involvement. Autologous hematopoietic stem cell transplant is an emerging treatment for this condition, that has ... Full text Link to item Cite

Large-Scale Characterization of Systemic Sclerosis Serum Protein Profile: Comparison to Peripheral Blood Cell Transcriptome and Correlations With Skin/Lung Fibrosis.

Journal Article Arthritis Rheumatol · April 2021 OBJECTIVE: To provide a large-scale assessment of serum protein dysregulation in diffuse cutaneous systemic sclerosis (dcSSc) and to investigate serum protein correlates of SSc fibrotic features. METHODS: We investigated serum protein profiles of 66 partic ... Full text Link to item Cite

Phase I dose escalation study of naive T-cell depleted donor lymphocyte infusion following allogeneic stem cell transplantation.

Journal Article Bone Marrow Transplant · January 2021 Prophylactic donor lymphocyte infusions (DLI) are used to augment post-transplant immune recovery to reduce both infectious complications and disease recurrence. Preclinical studies implicate the naive T-cell subset as the primary driver of graft-versus-ho ... Full text Link to item Cite

Clinical and Neuroimaging Correlates of Post-Transplant Delirium.

Journal Article Biol Blood Marrow Transplant · December 2020 Delirium is common among adults undergoing hematopoietic stem cell transplantation (HCT), although the clinical and neuroimaging correlates of post-HCT delirium have not been adequately delineated. We therefore examined the frequency of delirium and neuroi ... Full text Link to item Cite

Machine learning predicts stem cell transplant response in severe scleroderma.

Journal Article Ann Rheum Dis · December 2020 OBJECTIVE: The Scleroderma: Cyclophosphamide or Transplantation (SCOT) trial demonstrated clinical benefit of haematopoietic stem cell transplant (HSCT) compared with cyclophosphamide (CYC). We mapped PBC (peripheral blood cell) samples from the SCOT clini ... Full text Link to item Cite

Pre-Transplant Marital Status and Hematopoietic Cell Transplantation Outcomes.

Journal Article Curr Oncol · December 2020 BACKGROUND: Evidence about the impact of marital status before hematopoietic cell transplantation (hct) on outcomes after hct is conflicting. METHODS: We identified patients 40 years of age and older within the Center for International Blood and Marrow Tra ... Full text Link to item Cite

Pre-Transplant Marital Status and Hematopoietic Cell Transplantation Outcomes.

Journal Article Curr Oncol · December 1, 2020 Background: Evidence about the impact of marital status before hematopoietic cell transplantation (hct) on outcomes after hct is conflicting. Methods: We identified patients 40 years of age and older within the Center for International Blood and Marrow Tra ... Full text Link to item Cite

Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial.

Journal Article The Lancet. Respiratory medicine · October 2020 BackgroundA phase 2 trial of tocilizumab showed preliminary evidence of efficacy in systemic sclerosis. We assessed skin fibrosis and systemic sclerosis-associated interstitial lung disease (SSc-ILD) in a phase 3 trial to investigate the safety an ... Full text Cite

Pre-transplant hepatic steatosis (fatty liver) is associated with chronic graft-vs-host disease but not mortality.

Journal Article PLoS One · 2020 Allogeneic-HCT (allo-HCT), while potentially curative, can result in significant complications including graft versus host disease (GVHD). Prior studies suggest that metabolic syndrome may be one risk factor for GVHD. We hypothesized that hepatic steatosis ... Full text Link to item Cite

Recombinant Zoster Vaccine Significantly Reduces the Impact on Quality of Life Caused by Herpes Zoster in Adult Autologous Hematopoietic Stem Cell Transplant Recipients: A Randomized Placebo-Controlled Trial (ZOE-HSCT).

Journal Article Biol Blood Marrow Transplant · December 2019 Herpes zoster (HZ) can have a substantial impact on quality of life (QoL). The vaccine efficacy (VE) of a recombinant zoster vaccine (RZV) was 68.2% (95% confidence interval [CI], 55.6% to 77.5%) in a phase 3 study in adult autologous hematopoietic stem ce ... Full text Link to item Cite

Application of stem cell transplantation in autoimmune diseases.

Journal Article Curr Opin Hematol · November 2019 PURPOSE OF REVIEW: Autologous hematopoietic stem cell transplantation (HSCT) is a promising therapeutic modality for severe autoimmune diseases. In this review, we will outline the immunological mechanisms and the clinical evidence and experiences for ther ... Full text Link to item Cite

Myeloablation followed by autologous stem cell transplantation normalises systemic sclerosis molecular signatures.

Journal Article Ann Rheum Dis · October 2019 OBJECTIVE: In the randomised scleroderma: Cyclophosphamide Or Transplantation (SCOT trial) (NCT00114530), myeloablation, followed by haematopoietic stem cell transplantation (HSCT), led to improved clinical outcomes compared with monthly cyclophosphamide ( ... Full text Link to item Cite

Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation: A Randomized Clinical Trial.

Journal Article JAMA · July 9, 2019 IMPORTANCE: Herpes zoster, a frequent complication following autologous hematopoietic stem cell transplantation (HSCT), is associated with significant morbidity. A nonlive adjuvanted recombinant zoster vaccine has been developed to prevent posttransplantat ... Full text Link to item Cite

Interrater Reliability of Clinical Grading Measures for Cutaneous Chronic Graft-vs-Host Disease.

Journal Article JAMA Dermatol · July 1, 2019 IMPORTANCE: Cutaneous chronic graft-vs-host disease (cGVHD) is common after allogeneic hematopoietic stem cell transplant and is often associated with poor patient outcomes. A reliable and practical method for assessing disease severity and response to the ... Full text Link to item Cite

Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation.

Journal Article Biol Blood Marrow Transplant · May 2019 Multiple sclerosis (MS) is a chronic, disabling, immune-mediated, demyelinating and degenerative disease of the central nervous system. Approved disease-modifying therapies may be incompletely effective in some patients with highly active relapsing disease ... Full text Link to item Cite

Bone marrow transplantation for adolescents and young adults with sickle cell disease: Results of a prospective multicenter pilot study.

Journal Article Am J Hematol · April 2019 We conducted a multicenter pilot investigation of the safety and feasibility of bone marrow transplantation (BMT) in adults with severe sickle cell disease (SCD) (NCT 01565616) using a reduced toxicity preparative regimen of busulfan (13.2 mg/kg), fludarab ... Full text Link to item Cite

How I treat refractory chronic graft-versus-host disease.

Journal Article Blood · March 14, 2019 Approximately 35% to 50% of patients otherwise cured of hematologic malignancies after allogeneic hematopoietic stem cell transplantation will develop the pleomorphic autoimmune-like syndrome known as chronic graft-versus-host disease (cGVHD). Since in 200 ... Full text Link to item Cite

Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts.

Journal Article Ann Rheum Dis · January 2019 OBJECTIVE: To assess survival and identify predictors of survival in patients with systemic sclerosis-interstitial lung disease (SSc-ILD) who participated in the Scleroderma Lung Studies (SLS) I and II. METHODS: SLS I randomised 158 patients with SSc-ILD t ... Full text Link to item Cite

Systemic Sclerosis as an Indication for Autologous Hematopoietic Cell Transplantation: Position Statement from the American Society for Blood and Marrow Transplantation.

Journal Article Biol Blood Marrow Transplant · October 2018 Systemic sclerosis is a progressive inflammatory disease that is frequently fatal and has limited treatment options. High-dose chemotherapy with autologous hematopoietic cell transplantation (AHCT) has been evaluated as treatment for this disease in observ ... Full text Open Access Link to item Cite

Country-Level Macroeconomic Indicators Predict Early Post-Allogeneic Hematopoietic Cell Transplantation Survival in Acute Lymphoblastic Leukemia: A CIBMTR Analysis.

Journal Article Biol Blood Marrow Transplant · September 2018 For patients with acute lymphoblastic leukemia (ALL), allogeneic hematopoietic cell transplantation (alloHCT) offers a potential cure. Life-threatening complications can arise from alloHCT that require the application of sophisticated health care delivery. ... Full text Link to item Cite

Use of the National Institutes of Health Consensus Guidelines Improves the Diagnostic Sensitivity of Gastrointestinal Graft-Versus-Host Disease.

Journal Article Arch Pathol Lab Med · September 2018 CONTEXT: - Graft-versus-host disease of the gastrointestinal tract is a common complication of hematopoietic stem cell transplant associated with significant morbidity and mortality. Accurate diagnosis can be difficult and is a truly clinicopathologic ende ... Full text Link to item Cite

Late Gastrointestinal Complications of Allogeneic Hematopoietic Stem Cell Transplantation in Adults.

Journal Article Biol Blood Marrow Transplant · April 2018 Gastrointestinal (GI) complications including graft-versus-host disease (GVHD) are a major cause of morbidity and mortality in allogenic stem transplant recipients. Although several studies have previously looked into the acute GI complications, fewer smal ... Full text Link to item Cite

An mHealth Pain Coping Skills Training Intervention for Hematopoietic Stem Cell Transplantation Patients: Development and Pilot Randomized Controlled Trial.

Journal Article JMIR Mhealth Uhealth · March 19, 2018 BACKGROUND: Pain is a challenge for patients following hematopoietic stem cell transplantation (HCT). OBJECTIVE: This study aimed to develop and test the feasibility, acceptability, and initial efficacy of a Web-based mobile pain coping skills training (mP ... Full text Link to item Cite

Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma.

Journal Article N Engl J Med · January 4, 2018 BACKGROUND: Despite current therapies, diffuse cutaneous systemic sclerosis (scleroderma) often has a devastating outcome. We compared myeloablative CD34+ selected autologous hematopoietic stem-cell transplantation with immunosuppression by means of 12 mon ... Full text Link to item Cite

High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma.

Journal Article Bone Marrow Transplant · January 2018 Single-agent high-dose melphalan (HDM, 200 mg/m2) has been the most commonly used conditioning regimen prior to autologous stem cell transplant, since its introduction in 1992. We used a more aggressive alkylator-based conditioning regimen in an attempt to ... Full text Link to item Cite

Efficacy and safety of high-dose chemotherapy with autologous stem cell transplantation in senior versus younger adults with newly diagnosed multiple myeloma.

Journal Article Hematol Oncol · December 2017 We retrospectively studied 340 fit patients with multiple myeloma (MM) who underwent autologous stem cell transplantation (ASCT). We hypothesized that progression-free survival (PFS) of older patients was non-inferior to that of younger patients after ASCT ... Full text Link to item Cite

Clinical risks and healthcare utilization of hematopoietic cell transplantation for sickle cell disease in the USA using merged databases.

Journal Article Haematologica · November 2017 Advances in allogeneic hematopoietic cell transplantation for sickle cell disease have improved outcomes, but there is limited analysis of healthcare utilization in this setting. We hypothesized that, compared to late transplantation, early transplantation ... Full text Link to item Cite

Adult Umbilical Cord Blood Transplantation Using Myeloablative Thiotepa, Total Body Irradiation, and Fludarabine Conditioning.

Conference Biol Blood Marrow Transplant · November 2017 Treatment-related mortality (TRM) remains elevated in adult patients undergoing umbilical cord blood transplantation (UCBT), including an early rise in TRM suggestive of excessive toxicity associated with the standard myeloablative total body irradiation ( ... Full text Link to item Cite

Manufacture of Autologous CD34+ Selected Grafts in the NIAID-Sponsored HALT-MS and SCOT Multicenter Clinical Trials for Autoimmune Diseases.

Journal Article Biol Blood Marrow Transplant · September 2017 To ensure comparable grafts for autologous hematopoietic cell transplantation (HCT) in the National Institute of Allergy and Infectious Diseases-sponsored Investigational New Drug protocols for multiple sclerosis (HALT-MS) and systemic sclerosis (SCOT), a ... Full text Link to item Cite

An mHealth Pain Coping Skills Training Intervention for Hematopoietic Stem Cell Transplantation Patients: Development and Pilot Randomized Controlled Trial (Preprint)

Journal Article · July 27, 2017 BACKGROUNDPain is a challenge for patients following hematopoietic stem cell transplantation (HCT). Full text Cite

Transplantation of Ex Vivo Expanded Umbilical Cord Blood (NiCord) Decreases Early Infection and Hospitalization.

Journal Article Biol Blood Marrow Transplant · July 2017 Delayed hematopoietic recovery contributes to increased infection risk following umbilical cord blood (UCB) transplantation. In a Phase 1 study, adult recipients of UCB stem cells cultured ex vivo for 3 weeks with nicotinamide (NiCord) had earlier median n ... Full text Link to item Cite

Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma.

Journal Article Biol Blood Marrow Transplant · February 2017 Comprehensive recommendations for maintenance therapy after autologous stem cell transplantation (ASCT) for patients with multiple myeloma (MM) have yet to be defined. Bortezomib has been utilized as maintenance therapy after ASCT, but data attesting to th ... Full text Link to item Cite

Adult Umbilical Cord Blood Transplantation Using Myeloablative Total Body Irradiation, Fludarabine, and Thiotepa Conditioning

Conference Blood · December 2, 2016 AbstractIntroduction: Umbilical cord blood (UCB) extends the curative potential of stem cell transplantation to adult patients without a suitable donor. The most commonly used myeloablative preparative regim ... Full text Cite

Universal Mask Usage for Reduction of Respiratory Viral Infections After Stem Cell Transplant: A Prospective Trial.

Journal Article Clin Infect Dis · October 15, 2016 BACKGROUND: Respiratory viral infections (RVIs) are frequent complications of hematopoietic stem cell transplant (HSCT). Surgical masks are a simple and inexpensive intervention that may reduce nosocomial spread. METHODS: In this prospective single-center ... Full text Link to item Cite

Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery.

Journal Article J Hematol Oncol · August 17, 2016 BACKGROUND: The binding of CXCR4 with its ligand (stromal-derived factor-1) maintains hematopoietic stem/progenitor cells (HSPCs) in a quiescent state. We hypothesized that blocking CXCR4/SDF-1 interaction after hematopoietic stem cell transplantation (HSC ... Full text Open Access Link to item Cite

The Diagnostic Yield of Site and Symptom-Based Biopsies for Acute Gastrointestinal Graft-Versus-Host Disease: A 5-Year Retrospective Review.

Journal Article Dig Dis Sci · March 2016 BACKGROUND: Graft-versus-host disease (GVHD) complicates half of hematopoietic stem cell transplants (HCT), and the gastrointestinal tract is commonly affected. Endoscopic biopsies have a key role in the diagnosis. The optimal procedure(s) to perform and s ... Full text Link to item Cite

Indications and Results of HLA-Identical Sibling Hematopoietic Cell Transplantation for Sickle Cell Disease.

Journal Article Biol Blood Marrow Transplant · February 2016 Although a number of published trials exist of HLA-identical sibling hematopoietic cell transplantation (HCT) for sickle cell disease (SCD) that span 2 decades, when and for whom this therapy should be pursued is a subject of debate. Assessments of the ris ... Full text Link to item Cite

Results of a Multicenter Pilot Investigation of Bone Marrow Transplantation in Adults with Sickle Cell Disease (STRIDE)

Conference Blood · December 3, 2015 AbstractBackground: Hematopoietic cell transplantation (HCT) for sickle cell disease (SCD) is potentially curative, yet applied sparingly in adults due in part to limited donor avai ... Full text Cite

Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma.

Journal Article J Clin Apher · June 2015 High-dose cyclophosphamide (Cy) is frequently employed for peripheral blood mobilization of hematopoietic stem cells before high-dose chemotherapy with autologous stem cell transplantation (ASCT) in multiple myeloma (MM). The benefit of mobilization with C ... Full text Link to item Cite

A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients.

Journal Article Blood · November 6, 2014 Recombinant herpes zoster (HZ) vaccines may be an alternative to the live-attenuated HZ vaccine for immunocompromised individuals. This was a phase 1/2, randomized, observer-blind, placebo-controlled study in adults with multiple myeloma, non-Hodgkin lymph ... Full text Link to item Cite

Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment.

Journal Article J Clin Invest · July 2014 BACKGROUND: Delayed hematopoietic recovery is a major drawback of umbilical cord blood (UCB) transplantation. Transplantation of ex vivo-expanded UCB shortens time to hematopoietic recovery, but long-term, robust engraftment by the expanded unit has yet to ... Full text Open Access Link to item Cite

Reduced-intensity allogeneic transplantation using alemtuzumab from HLA-matched related, unrelated, or haploidentical related donors for patients with hematologic malignancies.

Journal Article Biol Blood Marrow Transplant · February 2014 We present a comparative study on 124 patients with hematologic malignancies who had undergone reduced-intensity conditioning and then received a transplant from an HLA-matched related (MRD), an HLA-matched unrelated (MUD), or an HLA-haploidentical related ... Full text Link to item Cite

Stem cell transplantation in systemic sclerosis.

Journal Article Curr Opin Rheumatol · November 2013 PURPOSE OF REVIEW: The purpose of this review is to discuss recent published clinical and mechanistic studies on stem cell transplantation for systemic sclerosis and their implications for clinical practice. RECENT FINDINGS: Retrospective analyses of indep ... Full text Link to item Cite

Pre-engraftment syndrome after myeloablative dual umbilical cord blood transplantation: risk factors and response to treatment.

Journal Article Bone Marrow Transplant · July 2013 High fevers and/or rashes prior to neutrophil engraftment are frequently observed after umbilical cord blood (UCB) transplantation, and the condition is referred to as pre-engraftment syndrome (PES). Few studies have evaluated the risk factors for and trea ... Full text Open Access Link to item Cite

Gastric antral vascular ectasia and its clinical correlates in patients with early diffuse systemic sclerosis in the SCOT trial.

Journal Article J Rheumatol · April 2013 OBJECTIVE: To describe the prevalence and clinical correlates of endoscopic gastric antral vascular ectasia (GAVE; "watermelon stomach") in early diffuse systemic sclerosis (SSc). METHODS: Subjects with early, diffuse SSc and evidence of specific internal ... Full text Link to item Cite

Immune recovery in adult patients after myeloablative dual umbilical cord blood, matched sibling, and matched unrelated donor hematopoietic cell transplantation.

Journal Article Biol Blood Marrow Transplant · November 2012 Immunologic reconstitution after allogeneic hematopoietic cell transplantation is a critical component of successful outcome. Umbilical cord blood (UCB) transplantation in adult recipients is associated with slow and often inadequate immune recovery. We ch ... Full text Link to item Cite

Transplantation for autoimmune diseases in north and South America: a report of the Center for International Blood and Marrow Transplant Research.

Journal Article Biol Blood Marrow Transplant · October 2012 Hematopoietic cell transplantation (HCT) is an emerging therapy for patients with severe autoimmune diseases (AID). We report data on 368 patients with AID who underwent HCT in 64 North and South American transplantation centers reported to the Center for ... Full text Link to item Cite

Preemptive dosing of plerixafor given to poor stem cell mobilizers on day 5 of G-CSF administration.

Journal Article Bone Marrow Transplant · August 2012 Plerixafor, given on day 4 of G-CSF treatment is more effective than G-CSF alone in mobilizing hematopoietic progenitor cells. We tested a strategy of preemptive plerixafor use following assessment of the peak mobilization response to 5 days of G-CSF. Pati ... Full text Link to item Cite

Differential impact of inhibitory and activating Killer Ig-Like Receptors (KIR) on high-risk patients with myeloid and lymphoid malignancies undergoing reduced intensity transplantation from haploidentical related donors.

Journal Article Bone Marrow Transplant · June 2012 The impact of activating KIR (aKIR) and inhibitory KIR (iKIR) on OS, relapse-related mortality (RRM) and acute GVHD (aGVHD) was prospectively studied in 84 adults with high-risk hematologic malignancies receiving reduced intensity conditioning (RIC) T-cell ... Full text Link to item Cite

Outcomes of a 1-day nonmyeloablative salvage regimen for patients with primary graft failure after allogeneic hematopoietic cell transplantation.

Journal Article Bone Marrow Transplant · May 2012 Primary graft failure after allogeneic hematopoietic cell transplantation is a life-threatening complication. A shortened conditioning regimen may reduce the risk of infection and increase the chance of survival. Here, we report the outcome of 11 patients ... Full text Link to item Cite

Cell-based therapies

Chapter · January 1, 2012 Cell therapy describes the process of introducing new cells into a tissue in order to treat a disease. Cell therapies often focus on the treatment of hereditary diseases, with or without the addition of gene therapy. There are many potential forms of cell ... Full text Cite

Early post transplant (F-18) 2-fluoro-2-deoxyglucose positron emission tomography does not predict outcome for patients undergoing auto-SCT in non-Hodgkin and Hodgkin lymphoma.

Journal Article Bone Marrow Transplant · June 2011 Positron emission tomography (PET) in conjunction with computed tomography is a frequently used modality for staging patients with lymphoma. Utility of PET-computed tomography before or early following auto-SCT has not been as rigorously evaluated. We retr ... Full text Link to item Cite

Adult dual umbilical cord blood transplantation using myeloablative total body irradiation (1350 cGy) and fludarabine conditioning.

Journal Article Biol Blood Marrow Transplant · June 2011 High treatment-related mortality (TRM) and high graft failure rate are serious concerns in HLA-mismatched umbilical cord blood (UCB) transplantation with myeloablative conditioning. We conducted a prospective trial of dual UCB transplantation using modifie ... Full text Link to item Cite

Acute kidney injury in patients with systemic sclerosis participating in hematopoietic cell transplantation trials in the United States.

Journal Article Biol Blood Marrow Transplant · May 2011 Recipients of hematopoietic cell transplantation may be at risk for developing acute kidney injury (AKI), and this risk may be increased in patients who undergo transplantation for severe systemic sclerosis (SSc) due to underlying scleroderma renal disease ... Full text Link to item Cite

Renal shielding and dosimetry for patients with severe systemic sclerosis receiving immunoablation with total body irradiation in the scleroderma: cyclophosphamide or transplantation trial.

Journal Article Int J Radiat Oncol Biol Phys · March 15, 2011 PURPOSE: To describe renal shielding techniques and dosimetry in delivering total body irradiation (TBI) to patients with severe systemic sclerosis (SSc) enrolled in a hematopoietic stem cell transplant protocol. METHODS AND MATERIALS: The Scleroderma: Cyc ... Full text Link to item Cite

Feasibility of low-dose interleukin-2 therapy following T-cell-depleted nonmyeloablative allogeneic hematopoietic stem cell transplantation from HLA-matched or -mismatched family member donors.

Journal Article Cancer Invest · January 2011 INTRODUCTION: High relapse rates and infections remain primary causes of failure in nonmyeloablative transplantation. Interleukin-2 (IL-2) may stimulate the immune system and improve outcomes. The primary objective of this pilot study was to evaluate the f ... Full text Link to item Cite

Natural killer cell-enriched donor lymphocyte infusions from A 3-6/6 HLA matched family member following nonmyeloablative allogeneic stem cell transplantation.

Journal Article Biol Blood Marrow Transplant · August 2010 Infusing natural killer (NK) cells following transplantation may allow less infections and relapse with little risk of acute graft-versus-host disease (aGVHD). We delivered 51 total NK cell-enriched donor lymphocyte infusions (DLIs) to 30 patients followin ... Full text Link to item Cite

Stem-cell transplantation for sickle cell disease.

Journal Article N Engl J Med · March 11, 2010 Link to item Cite

Pulmonary, gonadal, and central nervous system status after bone marrow transplantation for sickle cell disease.

Journal Article Biol Blood Marrow Transplant · February 2010 We conducted a prospective, multicenter investigation of human-leukocyte antigen (HLA) identical sibling bone marrow transplantation (BMT) in children with severe sickle cell disease (SCD) between 1991 and 2000. To determine if children were protected from ... Full text Link to item Cite

Long Term Survival Following High-dose Sequential Therapy with Autologous Hematopoietic Cell Rescue for Multiple Myeloma

Conference · 2010 High-dose therapy (HDT) with autologous hematopoietic cell rescue (AHCR) improves survival in patients with multiple myeloma, but is not curative due to a continuous risk of relapse. One approach to try to reduce relapse is to optimize the pretransplant t ... Cite

"Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.

Journal Article Biol Blood Marrow Transplant · January 2010 The purpose of this study was to evaluate the efficacy and safety of short-course bortezomib, melphalan, prednisone (VMP) in previously untreated multiple myeloma as frontline therapy for transplant-ineligible patients and induction prior to autologous ste ... Full text Link to item Cite

Hematopoietic cell transplantation for autoimmune disease: updates from Europe and the United States.

Journal Article Biol Blood Marrow Transplant · January 2010 Considerable advances have been made in our understanding of the immunobiology of autoimmune disease and its treatment with hematopoietic cell transplantation (HCT). In autoimmune disorders, the reconstituted immune system following lymphoablation and auto ... Full text Link to item Cite

Therapy with mycophenolate mofetil for refractory acute and chronic GVHD.

Journal Article Bone Marrow Transplant · December 2009 We evaluated the pharmacokinetics and efficacy of oral mycophenolate mofetil (MMF) for treatment of refractory GVHD. In a prospective study of acute GVHD, 9 of 19 patients (47%) had a response and 10 (53%) had no improvement. Survival at 6 and 12 months af ... Full text Link to item Cite

Carbon monoxide diffusion capacity: how low can you go for hematopoietic cell transplantation eligibility?

Journal Article Biol Blood Marrow Transplant · April 2009 Current guidelines suggest that patients with a pretransplantation diffusion capacity of the lung for carbon monoxide (DLCO) < or = 60% are not ideal candidates for hematopoietic cell transplantation (HCT); however, recent studies suggest this criterion ma ... Full text Link to item Cite

Response and toxicity of donor lymphocyte infusions following T-cell depleted non-myeloablative allogeneic hematopoietic SCT from 3-6/6 HLA matched donors.

Journal Article Bone Marrow Transplant · February 2009 We report the outcome of early donor lymphocyte infusions (DLIs) after T-cell depleted non-myeloablative transplantation using stem cells from HLA-matched or mismatched donors. Sixty-nine patients with high-risk hematologic malignancies received DLI follow ... Full text Link to item Cite

Myeloablative intravenous busulfan/fludarabine conditioning does not facilitate reliable engraftment of dual umbilical cord blood grafts in adult recipients.

Journal Article Biol Blood Marrow Transplant · May 2008 The efficacy of once-daily intravenous busulfan with fludarabine as a preparative regimen for partially matched umbilical cord blood transplantation has not been formally studied. We randomized 10 adult patients with myeloid malignancies to receive either ... Full text Link to item Cite

Outcomes of a second non-myeloablative allogeneic stem cell transplantation following graft rejection.

Journal Article Bone Marrow Transplant · January 2008 Following initial graft rejection, a second attempt at allogeneic immunotherapy is often contemplated, but data on the success is limited. We therefore report on 11 patients with hematologic malignancies, renal cell cancer or marrow failure who underwent a ... Full text Link to item Cite

Fludarabine-based nonmyeloablative stem cell transplantation for sickle cell disease with and without renal failure: clinical outcome and pharmacokinetics.

Journal Article Biol Blood Marrow Transplant · December 2007 End-organ damage is common in patients with sickle cell disease (SCD) thereby limiting the use of allogeneic stem cell transplantation (SCT). We report the outcome of 2 adult SCD patients, 1 with end-stage renal disease (ESRD), who underwent fludarabine-ba ... Full text Link to item Cite

High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study.

Journal Article Blood · August 15, 2007 More effective therapeutic strategies are required for patients with poor-prognosis systemic sclerosis (SSc). A phase 2 single-arm study of high-dose immunosuppressive therapy (HDIT) and autologous CD34-selected hematopoietic cell transplantation (HCT) was ... Full text Link to item Cite

Matched-related donor transplantation for sickle cell disease: report from the Center for International Blood and Transplant Research.

Journal Article Br J Haematol · June 2007 We report outcomes after myeloablative haematopoietic cell transplantation (HCT) from human leucocyte antigen (HLA)-matched sibling donors in 67 patients with sickle cell disease transplanted between 1989 and 2002. The most common indications for transplan ... Full text Link to item Cite

Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution.

Journal Article J Clin Oncol · February 20, 2007 PURPOSE: Allogeneic transplantation is typically limited to younger patients having a matched donor. To allow a donor to be found for nearly all patients, we have used a nonmyeloablative conditioning regimen in conjunction with stem cells from a related do ... Full text Link to item Cite

Effect of myeloablative bone marrow transplantation on growth in children with sickle cell anaemia: results of the multicenter study of haematopoietic cell transplantation for sickle cell anaemia.

Journal Article Br J Haematol · February 2007 Although haematopoietic cell transplantation (HCT) is curative for sickle cell anaemia (SCA), concerns about its short- and long-term toxicities limit its application. A potential toxicity is an adverse effect on growth. To identify an HCT growth effect, s ... Full text Link to item Cite

TU‐EE‐A2‐05: Challenges in Limiting Kidney Dose When Delivering Total Body Irradiation (TBI) for Patients with Severe Systemic Sclerosis (SSc)

Conference Medical Physics · January 1, 2007 Purpose: To describe challenges in limiting kidney dose when delivering TBI to SSc patients enrolled on a multicenter Phase II/III SCOT (Scleroderma Cyclophosphamide or Transplantation) protocol. Material and Methods: The SCOT protocol uses a preparative r ... Full text Cite

Cyclophosphamide in scleroderma lung disease.

Journal Article N Engl J Med · September 14, 2006 Link to item Cite

Allogeneic marrow transplantation in patients with severe systemic sclerosis: resolution of dermal fibrosis.

Journal Article Arthritis Rheum · June 2006 OBJECTIVE: To evaluate the safety and efficacy of allogeneic hematopoietic cell transplantation (HCT) after myeloablative conditioning in patients with severe systemic sclerosis (SSc). METHODS: Eligibility criteria for the study included SSc patients with ... Full text Link to item Cite

Chronic graft-versus-host disease.

Journal Article Blood Rev · January 2006 Chronic graft versus host disease (GVHD) remains today one of the most vexing late complications of allogeneic stem cell transplantation. Occurring a minimum of 100 days following stem cell transplantation, approximately 50% of patients will experience som ... Full text Link to item Cite

Outcome and Immune Reconstitution Following T Cell Depleted Nonmyeloablative Allogeneic Transplantation Using Matched Donors.

Conference Blood · November 16, 2005 AbstractTo minimize toxicity and monitor immune recovery without interference of long term use of immunosuppressive agents, we have investigated T-cell depleted, nonmyeloablative allogeneic therapy using mat ... Full text Cite

Recovery from and consequences of severe iatrogenic lymphopenia (induced to treat autoimmune diseases).

Journal Article Clin Immunol · December 2004 To ascertain the consequences of severe leukopenia and the tempo of recovery, we studied the immunity of 56 adult patients treated for multiple sclerosis or systemic sclerosis with autologous CD34 cell transplantation using extremely lymphoablative conditi ... Full text Link to item Cite

Hematopoietic Cell Transplantation for Sickle Cell Disease: Updated Results of the Multicenter Trial.

Conference Blood · November 16, 2004 AbstractBetween 1991 and 2000, 59 children with symptomatic sickle cell disease (SCD) were enrolled in a multicenter investigation of myeloablative HLA-identical sibling bone marrow transplantation (BMT). Pa ... Full text Cite

Adult recipients of umbilical cord blood transplants after nonmyeloablative preparative regimens.

Journal Article Biol Blood Marrow Transplant · August 2004 We report the outcome of 13 patients with advanced malignancies who underwent nonmyeloablative conditioning therapy followed by infusion of partially matched unrelated cord blood cells. The median age of these patients was 49 years, and their median weight ... Full text Link to item Cite

Medical expert systems

Journal Article Information Sciences · May 17, 2004 Full text Cite

Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan.

Journal Article Medicine (Baltimore) · May 2004 : To determine and directly compare the clinical course of white and Asian patients with paroxysmal nocturnal hemoglobinuria (PNH), data were collected for epidemiologic analysis on 176 patients from Duke University and 209 patients from Japan. White patie ... Full text Link to item Cite

Case based reasoning for medical decision-support in a safety critical environment

Journal Article Lecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics) · December 1, 2003 Case-based reasoning systems applied to safety-critical environments justify specific measures to ensure that the assistance provided is not dangerous to human life. This article presents a case-based reasoning system developed for medical decision-support ... Full text Cite

Invasive pneumococcal infections in children with sickle cell disease in the era of penicillin prophylaxis, antibiotic resistance, and 23-valent pneumococcal polysaccharide vaccination.

Journal Article J Pediatr · October 2003 Rates and severity of pneumococcal infections in children with sickle cell disease were examined before licensure of pneumococcal-conjugated vaccine (PVC). Rates of peak invasive infection rates in 1-year-old children with hemoglobin SS and mortality in th ... Full text Link to item Cite

High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis.

Journal Article Blood · October 1, 2003 There were 26 patients enrolled in a pilot study of high-dose immunosuppressive therapy (HDIT) for severe multiple sclerosis (MS). Median baseline expanded disability status scale (EDSS) was 7.0 (range, 5.0-8.0). HDIT consisted of total body irradiation, c ... Full text Link to item Cite

Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases.

Journal Article Biol Blood Marrow Transplant · September 2003 High-dose immunosuppressive therapy followed by autologous hematopoietic stem cell transplantation (HSCT) is currently being evaluated for the control of severe autoimmune diseases. The addition of antithymocyte globulin (ATG) to high-dose chemoradiotherap ... Full text Link to item Cite

Incidence, risk factors, and mortality from pneumonia developing late after hematopoietic stem cell transplantation.

Journal Article Bone Marrow Transplant · September 2003 The incidence, etiology, outcome, and risk factors for developing pneumonia late after hematopoietic stem cell transplantation (SCT) were investigated in 1359 patients transplanted in Seattle. A total of 341 patients (25% of the cohort) developed at least ... Full text Link to item Cite

Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia.

Journal Article Biol Blood Marrow Transplant · August 2003 We describe previously transfused patients with sickle cell disease (n = 6) and thalassemia (n = 1) who received nonmyeloablative hematopoietic stem cell transplantation (HCT) to induce stable (full or partial) donor engraftment. Patients were 3 to 20 year ... Full text Link to item Cite

Polymyositis as a manifestation of chronic graft-versus-host disease.

Journal Article Rheumatology (Oxford) · January 2003 Featured Publication OBJECTIVE: Chronic graft-versus-host disease (GVHD) after haematopoietic stem cell transplantation (HSCT) has similarities to some idiopathic autoimmune diseases, including polymyositis. To investigate the relationship between chronic GVHD and idiopathic m ... Full text Link to item Cite

Chronic graft-versus-host disease after allogeneic stem cell transplantation

Journal Article Turkish Journal of Cancer · January 1, 2003 Chronic Graft-versus-Host disease (chronic GVHD) is a clinicopathological syndrome which is the major determinant of long-term outcome and quality of life after allogeneic bone marrow or peripheral stem cell transplantation. Chronic GVHD may develop within ... Cite

High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes.

Journal Article Blood · September 1, 2002 Featured Publication Systemic sclerosis (SSc) is a multisystem disease of presumed autoimmune pathogenesis for which no proven effective treatment exists. High-dose immunosuppressive therapy (HDIT) has been proposed as an investigational treatment for severe autoimmune disease ... Link to item Cite

Bone marrow transplantation for non-malignant disease.

Journal Article Int J Hematol · August 2002 Featured Publication Full text Link to item Cite

Morbidity and mortality of chronic GVHD after hematopoietic stem cell transplantation from HLA-identical siblings for patients with aplastic or refractory anemias.

Journal Article Biol Blood Marrow Transplant · 2002 Featured Publication We analyzed effects of successive changes in prevention and treatment of chronic GVHD in 405 patients with aplastic anemia and refractory anemia given HLA-matched hematopoietic stem cell transplantation (HSCT) from 1970-1997. For analysis, patients were di ... Full text Link to item Cite

Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease.

Journal Article Transplantation · December 27, 2001 BACKGROUND: In a pilot trial we evaluated the toxicity and efficacy of sirolimus (rapamycin) as second-line therapy for the treatment of acute graft-versus-host disease (GVHD) in 21 patients (1-46 years of age) after allogeneic hematopoietic stem cell tran ... Full text Link to item Cite

Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies.

Journal Article Blood · December 15, 2001 Featured Publication In the early 1990s, 4 randomized studies compared conditioning regimens before transplantation for leukemia with either cyclophosphamide (CY) and total-body irradiation (TBI), or busulfan (Bu) and CY. This study analyzed the long-term outcomes for 316 pati ... Full text Link to item Cite

Immunity of patients surviving 20 to 30 years after allogeneic or syngeneic bone marrow transplantation.

Journal Article Blood · December 15, 2001 Featured Publication The duration of immunodeficiency following marrow transplantation is not known. Questionnaires were used to study the infection rates in 72 patients surviving 20 to 30 years after marrow grafting. Furthermore, in 33 of the 72 patients and in 16 donors (sib ... Full text Link to item Cite

The clinical course of PNH in the USA and in Japan.

Journal Article BLOOD · November 16, 2001 Link to item Cite

Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease.

Journal Article Ann Rheum Dis · June 2001 BACKGROUND: Systemic sclerosis (SSc, scleroderma) in either its diffuse or limited skin forms has a high mortality when vital organs are affected. No treatment has been shown to influence the outcome or significantly affect the skin score, though many form ... Full text Link to item Cite

Bone density loss after allogeneic hematopoietic stem cell transplantation: a prospective study.

Journal Article Biol Blood Marrow Transplant · 2001 Featured Publication The incidence and course of bone density abnormalities following hematopoietic stem cell transplantation are poorly understood and complicated by the impact of multiple factors. Hip, spine, and wrist bone mineral densities (BMDs) were measured in 104 adult ... Full text Link to item Cite

Secondary failure of platelet recovery after hematopoietic stem cell transplantation.

Journal Article Biol Blood Marrow Transplant · 2001 Featured Publication After primary recovery of platelet counts after transplantation, there can be a late persistent decline called secondary failure of platelet recovery (SFPR), which may occur although the counts of other cell lineages remain within the normal range. SFPR wa ... Full text Link to item Cite

Preventing opportunistic infections after hematopoietic stem cell transplantation: the Centers for Disease Control and Prevention, Infectious Diseases Society of America, and American Society for Blood and Marrow Transplantation Practice Guidelines and beyond.

Journal Article Hematology Am Soc Hematol Educ Program · 2001 Featured Publication This review presents evidence-based guidelines for the prevention of infection after blood and marrow transplantation. Recommendations apply to all myeloablative transplants regardless of recipient (adult or child), type (allogeneic or autologous) or sourc ... Full text Link to item Cite

Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia.

Journal Article Biol Blood Marrow Transplant · 2001 Featured Publication A multicenter investigation of allogeneic bone marrow transplantation for children with sickle cell disease was conducted that included 27 European and North American transplant centers. Fifty-nine patients who ranged in age from 3.3 to 15.9 years (median, ... Full text Link to item Cite

Managing Personnel through Staff Scheduling Algorithms

Journal Article Proceedings of the Joint Conference on Information Sciences · December 1, 2000 This article presents a literature review of the current state of staff scheduling, in particular nurse scheduling. In current health care service, the critical problem in nurse scheduling in a hospital is how to determine day-to-day shift assignments of e ... Cite

Research on Medical Informatics and Telemedicine

Journal Article Proceedings of the Joint Conference on Information Sciences · December 1, 2000 This paper addresses concisely the approach taken to research the area of Medical Informatics for the Oncology Department at Duke University Medical Center. The basic ideas behind medical informatics and telemedicine will be presented and how both are rela ... Cite

Applications of Computer Simulation in Medical Scheduling

Journal Article Proceedings of the Joint Conference on Information Sciences · December 1, 2000 In current health care service, it's important to minimize staff idle time and maintain a high utilization rate of the medical facilities. More and more hospitals, however, recognize waiting is a universal and serious problem for patients. The critical pro ... Cite

Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities.

Journal Article Bone Marrow Transplant · November 2000 This retrospective study describes the outcome in 53 patients who had immunosuppressive treatment changed from cyclosporine (CSP) to tacrolimus for resistant acute GVHD (n = 23), hemolytic uremic syndrome (HUS) (n = 13) or CSP-associated neurotoxicity (n = ... Full text Link to item Cite

Impact of a randomized, controlled trial of liberal vs conservative hospital discharge criteria on energy, protein, and fluid intake in patients who received marrow transplants.

Journal Article J Am Diet Assoc · September 2000 Featured Publication OBJECT: To determine if adult patients who received marrow transplants had faster resumption of oral energy and nutrient intake and shorter duration of intravenous (i.v.) fluid requirement if discharged from the hospital earlier than is customary. DESIGN: ... Full text Link to item Cite

Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Multicenter investigation of bone marrow transplantation for sickle cell disease.

Journal Article Blood · March 15, 2000 Featured Publication Fifty children who had symptomatic sickle cell disease received matched sibling marrow allografts between September 1991 and March 1999, with Kaplan-Meier probabilities of survival and event-free survival of 94% and 84%, respectively. Twenty-six patients ( ... Link to item Cite

Impact of bone marrow transplantation for symptomatic sickle cell disease: An interim report

Journal Article Blood · March 15, 2000 Fifty children who had symptomatic sickle cell disease received matched sibling marrow allografts between September 1991 and March 1999, with Kaplan- Meier probabilities of survival and event-free survival of 94% and 84%, respectively. Twenty-six patients ... Cite

Late complications of hematopoietic stem cell transplantation

Chapter · January 1, 2000 I. INTRODUCTION Stem cell transplantation of peripheral blood or bone marrow has evolved into an accepted treatment for a variety of life-threatening hematological, neoplastic, and immunological disorders. The numbers and types of transplants have increase ... Cite

New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia.

Journal Article J Clin Oncol · January 2000 Featured Publication PURPOSE: To determine the incidence of and risk factors for second malignancies after allogeneic bone marrow transplantation (BMT) for childhood leukemia. PATIENTS AND METHODS: We studied a cohort of 3, 182 children diagnosed with acute leukemia before the ... Full text Link to item Cite

Conditional and unconditional estimation of multidimensional quality of life after hematopoietic stem cell transplantation: a longitudinal follow-up of 415 patients.

Journal Article Biol Blood Marrow Transplant · 2000 Featured Publication Emerging literature suggests that quality of life (QOL) after bone marrow transplantation is relatively good but is accompanied in some patients by a variety of residual difficulties. The studies supporting this finding, however, have been somewhat limited ... Full text Link to item Cite

Bone Marrow Transplantation for Non-Malignant Disease.

Journal Article Hematology Am Soc Hematol Educ Program · 2000 Featured Publication This article reviews the experience in hematopoietic stem cell transplantation (HSCT) for non-malignant disease. HSCT has long been applied as treatment of life-threatening congenital immunodeficiency and metabolic diseases. In Section I, Dr. Parkman revie ... Full text Link to item Cite

Late effects of hematopoietic stem cell transplantation

Journal Article Hematology · January 1, 2000 Full text Cite

Changing from cyclosporine to tacrolimus as salvage therapy for chronic graft-versus-host disease.

Journal Article Biol Blood Marrow Transplant · 2000 Chronic graft-versus-host disease (GVHD) is the principal cause of transplantation-related morbidity and nonrelapse mortality late after allogeneic hematopoietic stem cell transplantation. The safety and potential efficacy of tacrolimus for the salvage tre ... Full text Link to item Cite

Physician participation in research surveys. A randomized study of inducements to return mailed research questionnaires.

Journal Article Eval Health Prof · December 1999 The authors randomly selected 400 physicians from a population of 1,545 practicing physicians providing follow-up care to patients who received bone marrow or blood stem cell transplants at the Fred Hutchinson Cancer Research Center to determine interest i ... Full text Link to item Cite

Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study.

Journal Article Blood · October 1, 1999 We evaluated 18,014 patients who underwent allogeneic bone marrow transplantation (BMT) at 235 centers worldwide to examine the incidence of and risk factors for posttransplant lymphoproliferative disorders (PTLD). PTLD developed in 78 recipients, with 64 ... Link to item Cite

Pathophysiology and treatment of graft-versus-host disease.

Journal Article Hematol Oncol Clin North Am · October 1999 Acute graft-versus-host disease denotes a distinctive syndrome characterized by a triad of dermatitis (rash), hepatitis (jaundice), and gastroenteritis (abdominal pain, diarrhea) developing in the first 100 days after allogeneic hematopoietic cell transpla ... Full text Link to item Cite

Autologous haematopoietic stem cell transplants for autoimmune disease--feasibility and transplant-related mortality. Autoimmune Disease and Lymphoma Working Parties of the European Group for Blood and Marrow Transplantation, the European League Against Rheumatism and the International Stem Cell Project for Autoimmune Disease.

Journal Article Bone Marrow Transplant · October 1999 This ongoing multicentre prospective phase I/II trial enrolled 74 consecutive patients from 22 centres worldwide with severe autoimmune disease, 35 with rheumatological disorders, 31 with neurological, five with haematological and three with vasculitides. ... Full text Link to item Cite

Hepatitis C virus infection and bone marrow transplantation: a cohort study with 10-year follow-up.

Journal Article Hepatology · June 1999 Before the introduction of routine blood donor screening in 1991, marrow transplant recipients were at significant transfusion-associated risk for infection with hepatitis C virus (HCV). We followed a cohort of 355 patients undergoing transplant in Seattle ... Full text Link to item Cite

Cirrhosis of the liver in long-term marrow transplant survivors.

Journal Article Blood · May 15, 1999 Featured Publication Patients who survive hematopoietic cell transplantation (HCT) have multiple risk factors for chronic liver disease, including hepatitis virus infection, iron overload, and chronic graft-versus-host disease (GVHD). We studied 3,721 patients who had survived ... Link to item Cite

Reduced dose intravenous immunoglobulin does not decrease transplant-related complications in adults given related donor marrow allografts.

Journal Article Biol Blood Marrow Transplant · 1999 Featured Publication Graft-vs.-host disease (GVHD) and infection are major complications of allogeneic bone marrow transplantation. Intravenous immunoglobulin (IVIg) given at a dose of 500 mg/kg/wk has been shown to decrease the risk of acute GVHD, interstitial pneumonia, and ... Full text Link to item Cite

Secure JAVA applets and applications: Guidelines and lessons learnt from the JAVA security model

Journal Article JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION · January 1, 1999 Link to item Cite

Association between pretransplant interferon-alpha and outcome after unrelated donor marrow transplantation for chronic myelogenous leukemia in chronic phase.

Journal Article Blood · July 15, 1998 Featured Publication Treatment options for patients diagnosed with chronic myelogenous leukemia (CML) in chronic phase (CP) who lack a suitable related donor for marrow transplantation include hydroxyurea, interferon-alpha (IFN-alpha), or transplantation from an unrelated dono ... Link to item Cite

The development of chronic graft-versus-host disease: an analysis of screening studies and the impact of corticosteroid use at 100 days after transplantation.

Journal Article Bone Marrow Transplant · July 1998 The value of routine chronic graft-versus-host disease (GVHD) screening studies performed between 70 and 120 days after allogeneic marrow transplantation was retrospectively evaluated among 241 patients. All patients received methotrexate and cyclosporine ... Full text Link to item Cite

Current and future preparative regimens for bone marrow transplantation in thalassemia.

Journal Article Ann N Y Acad Sci · June 30, 1998 Featured Publication Preparative regimens for marrow allografts in thalassemia have two objectives. One is eradication of diseased marrow and the other suppression of host-versus-graft (HVG) reactions so that the allograft survives. A common regimen to accomplish these goals h ... Full text Link to item Cite

Unrelated and HLA-nonidentical related donor marrow transplantation for thalassemia and leukemia. A combined report from the Seattle Marrow Transplant Team and the International Bone Marrow Transplant Registry.

Journal Article Ann N Y Acad Sci · June 30, 1998 Featured Publication Allogeneic marrow transplantation is curative therapy for thalassemia, but fewer than 30% of patients have an HLA-identical sibling marrow donor. Selection of alternative donors of hematopoietic stem cells (unrelated individuals or HLA-nonidentical family ... Full text Link to item Cite

Body weight and outcome of hematopoietic stem cell transplantation.

Journal Article Am J Med · June 1998 Featured Publication Full text Link to item Cite

Long-term outcome after marrow transplantation for severe aplastic anemia.

Journal Article Blood · May 15, 1998 Featured Publication We reviewed the records and reevaluated 212 patients with aplastic anemia transplanted at the Fred Hutchinson Cancer Research Center (FHCRC) between 1970 and 1993 who survived >/=2 years and who have been followed for up to 26 years. Parameters analyzed in ... Link to item Cite

Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia.

Journal Article N Engl J Med · April 2, 1998 Featured Publication BACKGROUND: Chronic myeloid leukemia can be cured by marrow transplantation from an HLA-identical sibling donor. The use of transplants from unrelated donors is an option for the 70 percent of patients without an HLA-identical sibling, but the morbidity an ... Full text Link to item Cite

Course of Crohn's disease after allogeneic marrow transplantation.

Journal Article Gastroenterology · March 1998 Featured Publication BACKGROUND & AIMS: Remission of several autoimmune diseases has been described after allogeneic marrow transplantation. The aim of this study was to determine if the natural history of Crohn's disease was altered by hematopoietic cell transplants from heal ... Full text Link to item Cite

Case-based reasoning in care-partner: Gathering evidence for evidence-based medical practice

Conference Lecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics) · January 1, 1998 This paper presents the CARE-PARTNER system. Functionally, it offers via the WWW knowledge-support assistance to clinicians responsible for the long-term follow-up of stem-cell post-transplant patient care. CAREPARTNER aims at implementing the concept of e ... Full text Cite

Avascular necrosis following bone marrow transplantation: a case-control study.

Journal Article Bone · January 1998 Featured Publication The role of specific immunosuppressive agents in the development of avascular necrosis (AVN) following hematopoietic stem cell and solid organ transplantation remains unclear. To further explore this question, we conducted a case-control study of patients ... Full text Link to item Cite

CARE-PARTNER: a computerized knowledge-support system for stem-cell post-transplant long-term follow-up on the World-Wide-Web.

Journal Article Proc AMIA Symp · 1998 Featured Publication Evidence-based practice in medicine promotes the performance of medicine based upon proven and validated practice. The CARE-PARTNER system presented here is a computerized knowledge-support system for stem-cell post-transplant long-term follow-up (LTFU) ca ... Link to item Cite

Intravenous immunoglobulin and the risk of hepatic veno-occlusive disease after bone marrow transplantation.

Journal Article Biol Blood Marrow Transplant · 1998 Recent reports using historical controls or registry cohorts suggest, respectively, either an increase in the mortality or a decrease in the incidence of hepatic veno-occlusive disease (VOD) with the administration of intravenous immunoglobulin (i.v.Ig) af ... Full text Link to item Cite

Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease.

Journal Article Blood · December 15, 1997 Featured Publication Chronic graft-versus-host disease (GVHD) is likely caused by donor T lymphocytes. Because unmodified blood stem cell grafts contain one log more T lymphocytes than unmodified marrow grafts, we evaluated the incidence of chronic GVHD in previously reported ... Link to item Cite

Safeguarding the administration of high-dose chemotherapy: a national practice survey by the American Society for Blood and Marrow Transplantation.

Journal Article Biol Blood Marrow Transplant · December 1997 Featured Publication Overdoses of high-dose chemotherapy before hematopoietic cell transplantation are serious adverse events, but their frequency and etiology are unknown. The American Society for Blood and Marrow Transplantation (ASBMT) conducted an anonymous national survey ... Link to item Cite

Collaborative multicenter investigation of marrow transplantation for sickle cell disease: current results and future directions.

Journal Article Biol Blood Marrow Transplant · December 1997 Featured Publication We present updated results of a multicenter collaborative investigation of bone marrow transplantation for sickle cell disease. Between September 1991 and April 1997, thirty-four children less than 16 years of age with severe sickle cell disease received m ... Link to item Cite

Distributed Reuse of Knowledge in a Computerized Decision Support System for Bone-Marrow Post-Transplant Care over the World-Wide Web

Journal Article Journal of the American Medical Informatics Association · December 1, 1997 Cite

Methotrexate and cyclosporine for graft-vs.-host disease prevention: what length of therapy with cyclosporine?

Journal Article Biol Blood Marrow Transplant · October 1997 Featured Publication One hundred three patients with leukemia, aplastic anemia, or myelodysplastic syndrome were treated by marrow transplantation from genotypically HLA-identical siblings (n = 92) or HLA haploidentical family members differing for one HLA antigen on the nonsh ... Link to item Cite

Marrow transplants from unrelated donors for treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.

Journal Article Blood · August 15, 1997 Featured Publication Transplantation of marrow from unrelated donors was investigated in patients with Philadelphia chromosome-positive (Ph1+) acute lymphoblastic leukemia (ALL) who lacked a suitable family donor. Eighteen patients underwent transplantation at our center betwe ... Link to item Cite

Foundation for the Accreditation of Hematopoietic Cell Therapy (FAHCT) response to FDA (Docket no. 97N-0068). FAHCT Board of Directors.

Journal Article J Hematother · August 1997 We believe the proposed model is appropriate to our current state of knowledge and recognize that FDA regulations will evolved as the field evolves. We thank you for the opportunity to work with FDA as its regulatory strategy is developed in the near futur ... Full text Link to item Cite

Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA-matching, and marrow cell dose.

Journal Article Blood · June 1, 1997 Featured Publication Transplantation of hematopoietic stem cells from an HLA-compatible unrelated volunteer is an option for patients with acute leukemia lacking a family match. However, criteria for patient and donor selection and the most effective transplant procedures, inc ... Link to item Cite

Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: a prospective, randomized trial.

Journal Article Blood · May 15, 1997 Featured Publication Patients with a lymphohematopoietic malignancy considered to be at high risk for posttransplant relapse were enrolled in a study to compare the use of cyclosporine (CSP) as a single agent with a combination of methylprednisolone (MP) and CSP for graft-vers ... Link to item Cite

Longterm followup and quality of life after hematopoietic stem cell transplantation.

Journal Article J Rheumatol Suppl · May 1997 Featured Publication The success of marrow or blood stem cell transplantation may depend upon events arising months to years later. Transplant regimen related toxicity may include cataract formation due to corticosteroids or total body irradiation (TBI) and endocrine or gonada ... Link to item Cite

The evolving role of blood and marrow transplantation for the treatment of autoimmune diseases.

Journal Article J Rheumatol Suppl · May 1997 Featured Publication With over 4 decades of seminal contributions to the development and application of BMT, Dr. Thomas stresses the importance of collaboration between rheumatologists and transplant clinicians in developing this evolving area of treatment. While the debate co ... Link to item Cite

Pre-existing autoimmune disease in patients with long-term survival after allogeneic bone marrow transplantation.

Journal Article J Rheumatol Suppl · May 1997 Featured Publication We reviewed the experience with allogeneic bone marrow transplantation (BMT) at Fred Hutchinson Cancer Research Center and affiliated Seattle hospitals for patients with preexisting autoimmune diseases. The review was limited to patients who received trans ... Link to item Cite

Development of a protocol for allogeneic marrow transplantation for severe systemic sclerosis: paradigm for autoimmune disease.

Journal Article J Rheumatol Suppl · May 1997 Featured Publication Some types of severe autoimmune disease are associated with significant morbidity and a high mortality rate. Many of these cases occur in young adults who, even if they survive, become severely debilitated. Systemic sclerosis (SSc) is a paradigm for other ... Link to item Cite

Autologous stem cell transplantation for autoimmune diseases: issues in protocol development.

Journal Article J Rheumatol Suppl · May 1997 Featured Publication For patients with autoimmune disease resistant to conventional therapy, aggressive strategies employing high dose chemoradiotherapy and autologous stem cell transplant appear to be warranted. Support for this approach comes from animal studies employing ma ... Link to item Cite

Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation.

Journal Article Blood · April 15, 1997 The influence of busulfan (BU) plasma concentration on outcome of transplantation from HLA identical family members for the treatment of chronic myelogenous leukemia (CML) was examined in 45 patients transplanted in chronic phase (CP) (n = 39) or accelerat ... Link to item Cite

Quasielastic light scattering study of the living human lens as a function of age.

Journal Article Curr Eye Res · March 1997 PURPOSE: To determine contributions of molecular scattering elements to the increase with age in the light scattered from the human ocular lens in vivo. METHODS: We used quasielastic light scattering to measure autocorrelation functions of the intensity of ... Full text Link to item Cite

Infectious morbidity in long-term survivors of allogeneic marrow transplantation is associated with low CD4 T cell counts.

Journal Article Am J Hematol · February 1997 Featured Publication Survivors of allogeneic marrow transplants are immunodeficient for at least 1 year after grafting. Multiple defects of immunity have been found; however, it is not known which defect primarily accounts for the high infectious morbidity of these patients. T ... Full text Link to item Cite

A double-blind randomized trial comparing outpatient parenteral nutrition with intravenous hydration: effect on resumption of oral intake after marrow transplantation.

Journal Article JPEN J Parenter Enteral Nutr · 1997 Featured Publication BACKGROUND: Outpatient parenteral nutrition (PN) is often given to marrow transplant recipients after high-dose chemoradiotherapy until the resumption of adequate oral intake; however, it may adversely prolong resumption or oral calorie intake by contribut ... Full text Link to item Cite

Bone marrow transplantation for sickle cell disease.

Journal Article N Engl J Med · December 12, 1996 Full text Link to item Cite

FK506 in combination with methotrexate for the prevention of graft-versus-host disease after marrow transplantation from matched unrelated donors.

Journal Article Blood · November 1, 1996 Featured Publication The safety and potential efficacy of FK506 in combination with a short course of methotrexate (MTX) for the prevention of acute graft-versus-host disease (GVHD) after marrow transplantation from HLA-matched unrelated donors was evaluated in a single-arm Ph ... Link to item Cite

Bone marrow transplantation for sickle cell disease.

Journal Article N Engl J Med · August 8, 1996 Featured Publication BACKGROUND: We investigated the risks and benefits of allogeneic bone marrow transplantation in children with complications of sickle cell disease. METHODS: Twenty-two children less than 16 years of age who had symptomatic sickle cell disease received marr ... Full text Link to item Cite

Evaluation of a CD5-specific immunotoxin for treatment of acute graft-versus-host disease after allogeneic marrow transplantation.

Journal Article Blood · August 1, 1996 Featured Publication Acute graft-versus-host disease (GVHD) is most often treated with high dose glucocorticoids, but less than half of patients have durable overall improvement. Previous phase I and phase II studies suggested that treatment with a CD5-specific immunotoxin (Xo ... Link to item Cite

Graft-versus-host reactions: anti-leukemia effects of donor T cells.

Journal Article Transplant Proc · June 1996 Featured Publication Link to item Cite

Immunomodulation in allogeneic marrow transplantation: use of intravenous immune globulin to suppress acute graft-versus-host disease.

Journal Article Clin Exp Immunol · May 1996 Featured Publication Intravenous immune globulin (IVIG) has been used with success to prevent and treat infection in patients with immunodeficiencies of humoral immune function. More recently, IVIG has been shown to modulate immune responses and to treat successfully several a ... Link to item Cite

Barriers to bone marrow transplantation for sickle cell anemia.

Journal Article Biol Blood Marrow Transplant · May 1996 Featured Publication While allogeneic marrow transplantation is curative therapy for patients with sickle cell anemia, only a small fraction of patients in the United States receive this treatment. We surveyed participants in our multicenter study of marrow transplantation for ... Link to item Cite

Marrow transplantation for hepatitis-associated aplastic anemia: a follow-up of long-term survivors.

Journal Article Biol Blood Marrow Transplant · May 1996 Featured Publication Between 1971 and 1989 we have treated 19 patients with hepatitis-associated aplastic anemia by marrow transplantation from their HLA-identical siblings following conditioning with 200 mg/kg cyclophosphamide (Cy) administered over a period of 4 days. One pa ... Link to item Cite

Unrelated donor marrow transplantation for myelodysplasia (MDS) and MDS-related acute myeloid leukaemia.

Journal Article Br J Haematol · April 1996 Featured Publication Allogeneic marrow transplantation using related marrow donors for myelodysplasia (MDS) and acute myeloid leukaemia (AML) arising from MDS results in 35-56% actuarial disease-free survival. Because the use of unrelated donors has not been well-characterized ... Full text Link to item Cite

Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation.

Journal Article Blood · April 1, 1996 Patients successfully treated with a marrow transplant often have concerns about fertility and pregnancy. This study was performed to determine pregnancy outcome among patients who had received high-dose chemotherapy alone or with total-body irradiation (T ... Link to item Cite

Allogeneic marrow transplantation for aplastic anaemia associated with dyskeratosis congenita.

Journal Article Br J Haematol · March 1996 Featured Publication Eight patients with aplastic anaemia associated with dyskeratosis congenita received allogeneic marrow grafts from either HLA-identical siblings (six patients) or HLA-matched unrelated donors (two patients). Patients who received marrow from HLA-identical ... Full text Link to item Cite

Bone density loss during treatment of chronic GVHD.

Journal Article Bone Marrow Transplant · March 1996 Featured Publication Nine adult patients 31-47 (median 39) years of age treated with prednisone and cyclosporin A (CsA) for chronic graft-versus-host disease (GVHD) were evaluated for biochemical factors associated with skeletal turnover at initiation of immunosuppressive ther ... Link to item Cite

Marrow transplantation for Fanconi anaemia: conditioning with reduced doses of cyclophosphamide without radiation.

Journal Article Br J Haematol · March 1996 Nine patients with Fanconi anaemia (FA) were conditioned for HLA-identical sibling bone marrow transplant (BMT) with reduced dose of cyclophosphamide (Cy) without radiation or antithymocyte globulin (ATG). The total dose of Cy was 140 mg/kg (n = 2) or 120 ... Full text Link to item Cite

A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs.-host disease after marrow transplantation: clinical outcome and effect on subsequent immune recovery.

Journal Article Biol Blood Marrow Transplant · February 1996 Featured Publication To determine whether intravenous immunoglobulin (IVIg) given monthly from day 90 to day 360 posttransplantation decreased the incidence of late infection, chronic graft-vs.-host disease (GVHD), and obliterative bronchiolitis after marrow transplantation, p ... Link to item Cite

Bone marrow transplantation for severe aplastic anemia from genotypically HLA-nonidentical relatives. An update of the Seattle experience.

Journal Article Transplantation · January 15, 1996 Featured Publication This report updates the results of marrow transplantation at the Fred Hutchinson Cancer Research Center for patients with severe aplastic anemia whose donors were HLA-nonidentical relatives. Between 1970 and 1993, 40 patients received transplants for sever ... Full text Link to item Cite

Secondary immunodeficiencies and stem cell transplantation: issues of administration and safety of intravenous immunoglobulin.

Journal Article Clin Ther · 1996 Featured Publication This article reviews the administration, efficacy, and safety of prophylactic intravenous immunoglobulin in patients with secondary immunodeficiency and those undergoing allogeneic bone marrow transplantation. Associated infections in these immunosuppresse ... Full text Link to item Cite

Malignancies after marrow transplantation for aplastic anemia and fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients.

Journal Article Blood · January 1, 1996 Featured Publication Risk factors for the development of a new (secondary) malignancy after marrow transplantation are still incompletely defined. In the present study, we analyzed results in 700 patients with severe aplastic anemia treated with allogeneic marrow transplantati ... Link to item Cite

Allogeneic marrow transplantation for refractory anemia: a comparison of two preparative regimens and analysis of prognostic factors.

Journal Article Blood · January 1, 1996 Featured Publication From 1990 to 1993 we performed a prospective study of busulfan (16 mg/kg) and cyclophosphamide (120 mg/kg) in 30 patients with refractory anemia (RA) undergoing related (n = 17) or unrelated (n = 13) donor marrow transplantation. Nineteen patients survive ... Link to item Cite

Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors.

Journal Article J Clin Oncol · January 1996 PURPOSE: To determine if an intensive preparative regimen of busulfan (BU), cyclophosphamide (CY), and total-body irradiation (TBI) could improve outcome after marrow transplantation for advanced morphology myelodysplasia (refractory anemia with excess bla ... Full text Link to item Cite

IVIG in bone marrow transplantation

Journal Article P and T · January 1, 1996 The principal causes of allogeneic transplant-related mortality are graft- versus-host disease (GVHD), interstitial pneumonia, and cytomegalovirus (CMV) infection. In bone marrow-transplant recipients, intravenous immunoglobulin (IVIG) has shown the abilit ... Cite

Unrelated donor marrow transplantation in children.

Journal Article Blood · October 15, 1995 Eighty-eight children 0.5 to 17 years of age (median, 9 years of age) received an unrelated donor marrow transplant for treatment of chronic myeloid leukemia (CML; n = 16), acute lymphoblastic leukemia (ALL) in first or second remission (n = 15) or more ad ... Link to item Cite

A retrospective analysis of the long-term effect of splenectomy on late infections, graft-versus-host disease, relapse, and survival after allogeneic marrow transplantation for chronic myelogenous leukemia.

Journal Article Blood · September 1, 1995 Featured Publication The present study was performed as a retrospective analysis of the role of pretransplant splenectomy to determine the incidence of late bacterial infections, acute and chronic graft-versus-host disease (GVHD), relapse, and survival among 358 patients recei ... Link to item Cite

Immunosuppressive agents for prevention of graft-versus-host disease

Journal Article Bone Marrow Transplantation · July 26, 1995 Cite

A toxicity study of trimetrexate used in combination with cyclosporine as acute graft-versus-host disease prophylaxis in HLA-mismatched, related donor bone marrow transplants.

Journal Article Transplantation · July 15, 1995 Featured Publication This study evaluated the acute toxicity of trimetrexate (TMTX) used in combination with cyclosporine (CsA) for prevention of acute graft-versus-host disease (GVHD) in patients undergoing allogeneic marrow transplantation from HLA-mismatched, related donors ... Full text Link to item Cite

Cataracts after bone marrow transplantation: long-term follow-up of adults treated with fractionated total body irradiation.

Journal Article Int J Radiat Oncol Biol Phys · June 15, 1995 Featured Publication PURPOSE: To determine the risk of, and risk factors for, developing cataracts after bone marrow transplantation. METHODS AND MATERIALS: Four hundred and ninety-two adults who underwent bone marrow transplantation in Seattle were followed for 2 to 18 (media ... Full text Link to item Cite

Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: a single-center study.

Journal Article Blood · June 15, 1995 The pharmacokinetics, safety, and efficacy in marrow transplantation of FK506-based immunosuppression for graft-versus-host disease (GVHD) prophylaxis was evaluated in an open label pilot study of 18 patients. Patients more than 12 years of age (median, 35 ... Link to item Cite

Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients.

Journal Article Blood · May 1, 1995 We studied 346 patients after bone marrow transplantation (BMT) for chronic myeloid leukemia (CML) for the presence of the bcr-abl transcript detected by the polymerase chain reaction (PCR) to understand the frequency and implication of a positive test. A ... Link to item Cite

High-dose cyclophosphamide, carmustine, and etoposide followed by allogeneic bone marrow transplantation in patients with lymphoid malignancies who had received prior dose-limiting radiation therapy.

Journal Article J Clin Oncol · March 1995 PURPOSE: To evaluate a high-dose chemotherapy regimen without total-body irradiation (TBI) followed by allogeneic (allo) bone marrow transplantation (BMT) in patients with lymphoid malignancies who had received prior dose-limiting radiotherapy. PATIENTS AN ... Full text Link to item Cite

Neurologic complications after allogeneic marrow transplantation for sickle cell anemia.

Journal Article Blood · February 15, 1995 Featured Publication Seven of 21 patients with sickle cell anemia developed neurologic complications 5 to 243 days (median, 33 days) after allogeneic marrow transplantation. Among these 7 patients, indications for transplantation included either a past history of stroke (4 pat ... Link to item Cite

Quality of life of 125 adults surviving 6-18 years after bone marrow transplantation.

Journal Article Soc Sci Med · February 1995 Featured Publication BACKGROUND: Recent studies examining the medical and psychosocial sequelae of bone marrow transplantation have reported most survivors do relatively well while a smaller group continues to experience less than optimal quality of life (QOL). Many of these s ... Full text Link to item Cite

Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia.

Journal Article Blood · December 15, 1994 The records were reviewed of 58 patients receiving transplants in Seattle with unmanipulated marrow from HLA-identical siblings during the accelerated phase (AP) of chronic myeloid leukemia. Variables examined for association with survival and relapse incl ... Link to item Cite

Effect of graft-versus-host disease prophylaxis on relapse in patients transplanted for acute myeloid leukemia.

Journal Article Bone Marrow Transplant · December 1994 Between November 1978 and September 1988, 184 patients with acute myeloid leukemia in first remission received marrow transplants from HLA-identical siblings after conditioning with 120 mg/kg of cyclophosphamide and 12.0 Gy fractionated total body irradiat ... Link to item Cite

High-dose fractionated total-body irradiation, etoposide, and cyclophosphamide followed by autologous stem-cell support in patients with malignant lymphoma.

Journal Article J Clin Oncol · December 1994 PURPOSE: To evaluate a high-dose treatment regimen of fractionated total-body irradiation (TBI), etoposide, and cyclophosphamide (Cy) followed by autologous stem-cell transplantation (ASCT) in patients with malignant lymphoma. PATIENTS AND METHODS: Fifty-t ... Full text Link to item Cite

Complications of allogeneic bone marrow transplantation.

Journal Article Curr Opin Hematol · November 1994 Featured Publication Recent research has increased our understanding of the pathogenesis and prevention of the immediate and delayed complications of allogeneic bone marrow transplantation. Cytokines appear to play a major role in the pathogenesis of acute graft-versus-host di ... Link to item Cite

Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide.

Journal Article Blood · September 15, 1994 A prospective randomized study was conducted comparing two conditioning regimens for the treatment of patients with chronic myeloid leukemia in chronic phase by marrow transplantation from HLA identical siblings. Sixty-nine patients received 60 mg/kg of cy ... Link to item Cite

The management of chronic graft-versus-host disease.

Journal Article Blood Rev · September 1994 Featured Publication Chronic graft-versus-host disease (GVHD) is a major cause of late morbidity and mortality following allogeneic marrow transplantation. The pathogenesis and clinical features of chronic GVHD resemble those of several autoimmune diseases including progressiv ... Full text Link to item Cite

Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor.

Journal Article Blood · August 15, 1994 Humanized anti-Tac is a genetically engineered human IgG1 monoclonal antibody specific for Tac, the alpha subunit of the interleukin-2 (IL-2) receptor, and blocks IL-2-dependent activation of human T lymphocytes. The safety, pharmacokinetics, and immunosup ... Link to item Cite

Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia

Journal Article Blood · August 1, 1994 Graft rejection has been a problem after marrow grafts for patients with aplastic anemia who were conditioned with cyclophosphamide (CY). Rejection lessened when patients were given the marrow donor's peripheral blood buffy- coat cells in addition to the m ... Full text Cite

Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia.

Journal Article Blood · August 1, 1994 Graft rejection has been a problem after marrow grafts for patients with aplastic anemia who were conditioned with cyclophosphamide (CY). Rejection lessened when patients were given the marrow donor's peripheral blood buffy-coat cells in addition to the ma ... Link to item Cite

Reduction in transplant-related complications in patients given intravenous immuno globulin after allogeneic marrow transplantation.

Journal Article Clin Exp Immunol · July 1994 Featured Publication Bone marrow transplantation renders patients immunocompetent due to the need for supralethal doses of chemoradiotherapy prior to infusion of the donor stem cells. Multiple immunological deficiencies are seen and patients are at high risk of developing a va ... Link to item Cite

The case for the Clinton plan for health care reform.

Journal Article N Engl J Med · April 14, 1994 Link to item Cite

Spontaneous factor VIII inhibitor occurring in association with chronic graft-versus-host disease.

Journal Article Am J Hematol · March 1994 Featured Publication The development of spontaneously acquired Factor VIII inhibitors is rare and may lead to serious hemorrhagic sequelae. We report here the case of a patient who acquired a Factor VIII inhibitor two years after an allogeneic bone marrow transplant for CML. T ... Full text Link to item Cite

Bone marrow transplantation for sickle cell disease. The United States experience.

Journal Article Am J Pediatr Hematol Oncol · February 1994 Featured Publication PURPOSE: As of June 1992, five patients with sickle cell disease had been treated by matched sibling bone marrow transplantation in the United States. PATIENTS AND METHODS: Three patients underwent transplantations for complications related to sickle cell ... Link to item Cite

Bone marrow transplantation for thalassemia. The USA experience.

Journal Article Am J Pediatr Hematol Oncol · February 1994 Featured Publication PURPOSE: We have reviewed the results of bone marrow transplantation in 30 patients with thalassemia major who were treated in the United States. PATIENTS AND METHODS: Ten patients who underwent transplantation in Seattle and 20 patients from five other U. ... Link to item Cite

Marrow transplant experience for children with severe aplastic anemia.

Journal Article Am J Pediatr Hematol Oncol · February 1994 Featured Publication PURPOSE: The two major factors associated with lack of survival after allogeneic marrow transplant for severe aplastic anemia have been graft rejection and acute graft versus host disease (GVHD). As a result, survival for patients transplanted in the 1970s ... Link to item Cite

Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience.

Journal Article J Clin Oncol · December 1993 PURPOSE: To analyze results of 127 patients undergoing myeloablative therapy followed by marrow transplantation for relapsed or refractory Hodgkin's disease. PATIENTS AND METHODS: Twenty-three patients had primary refractory disease, 34 were in early first ... Full text Link to item Cite

Autologous bone marrow transplantation for acute lymphoblastic leukemia.

Journal Article Bone Marrow Transplant · October 1993 Between December 1979 and February 1991, 89 patients with ALL received autologous BMT. Median patient age was 18.4 years. Ten patients were in first remission, 52 were in second or greater remission and 27 were in relapse at the time of transplant. Conditi ... Link to item Cite

Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome.

Journal Article Blood · July 15, 1993 We treated 93 patients with myelodysplastic syndrome using cyclophosphamide and either total body irradiation (n = 88) or busulfan (n = 5) followed by marrow transplantation. Sixty-five marrow donors were genotypically HLA-identical siblings and 28 were ot ... Link to item Cite

Marrow transplantation for disorders of hematopoiesis.

Journal Article Leukemia · July 1993 Featured Publication Link to item Cite

Long-term survival and cure after marrow transplantation for congenital hypoplastic anaemia (Diamond-Blackfan syndrome).

Journal Article Br J Haematol · July 1993 Featured Publication Four patients with Diamond-Blackfan syndrome (congenital hypoplastic anaemia) whose disease was resistant to corticosteroid treatment and who were red blood cell transfusion-dependent, were given marrow grafts from allogeneic human-leucocyte-antigen (HLA)- ... Full text Link to item Cite

Autologous marrow transplantation for patients with acute myeloid leukemia in untreated first relapse or in second complete remission.

Journal Article J Clin Oncol · July 1993 PURPOSE: This study compares outcomes of autologous bone marrow transplantation (ABMT) in patients with acute myeloid leukemia (AML) in untreated first relapse (REL1) or in second complete remission (REM2). PATIENTS AND METHODS: Forty-seven patients with A ... Full text Link to item Cite

High-dose cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation in patients with lymphoid malignancies who have received dose-limiting radiation therapy.

Journal Article J Clin Oncol · July 1993 PURPOSE: To evaluate high-dose chemotherapy followed by autologous bone marrow transplantation (ABMT) in patients with lymphoid malignancy who had received prior radiation therapy. PATIENTS AND METHODS: Fifty-seven patients with non-Hodgkin's lymphoma (NHL ... Full text Link to item Cite

Recovery after allogeneic marrow transplantation: prospective study of predictors of long-term physical and psychosocial functioning.

Journal Article Bone Marrow Transplant · April 1993 Featured Publication No prospective data have documented the physical and psychosocial functioning of patients before and after BMT. In this study 67 allogeneic transplant patients completed standardized self-report measures pre-transplant. Survivors were re-assessed at 90 day ... Link to item Cite

Fatal eosinophilia myalgia syndrome in a marrow transplant patient attributed to total parenteral nutrition with a solution containing tryptophan.

Journal Article Bone Marrow Transplant · February 1993 Featured Publication A 16-year-old white male with acute biphenotypic leukemia developed evidence of the eosinophilia myalgia syndrome associated with total parenteral nutritional support with solutions containing tryptophan, which were given during his initial induction chemo ... Link to item Cite

Quality of life of adult long-term survivors of bone marrow transplantation: a qualitative analysis of narrative data.

Journal Article Oncol Nurs Forum · 1993 Featured Publication Recently, clinicians and researchers alike have challenged the long-standing impression that survivors of bone marrow transplantation (BMT) experience a less than optimal quality of life (QOL). Despite the accumulating evidence suggesting that most adult s ... Link to item Cite

Marrow transplantation from unrelated donors for treatment of hematologic malignancies: effect of mismatching for one HLA locus.

Journal Article Blood · January 1, 1993 One hundred twelve patients less than 36 years old received marrow grafts from unrelated donors as treatment for hematologic malignancy. Seventy donor/recipient pairs were phenotypically identical for HLA-A, -B, and -D, while 42 had a "minor" disparity at ... Link to item Cite

Allogeneic marrow transplantation during untreated first relapse of acute myeloid leukemia.

Journal Article J Clin Oncol · November 1992 Featured Publication PURPOSE: The purpose of this report was to review the Seattle experience in bone marrow transplantation (BMT) for acute myeloid leukemia (AML) during untreated first relapse. PATIENTS AND METHODS: Through 1990, 126 patients were transplanted during untreat ... Full text Link to item Cite

Two cases of transfusion-associated graft-vs-host disease after open heart surgery.

Journal Article Arch Dermatol · November 1992 Featured Publication BACKGROUND: Some cases of blood transfusion-associated (TA) graft-vs-host disease (GVHD) in immunocompetent patients have been reported, but those dermatologic findings were not precisely mentioned. We describe patients with clinicopathologically TA-GVHD a ... Link to item Cite

Treatment of acute graft-versus-host disease with a nonmitogenic anti-CD3 monoclonal antibody.

Journal Article Transplantation · November 1992 Featured Publication Treatment with the monoclonal antibody OKT3 specific for the CD3 complex associated with the T cell antigen receptor can reverse acute rejection of human renal allografts. However, efficacy of anti-CD3 antibodies for treatment of patients with acute graft- ... Full text Link to item Cite

Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate.

Journal Article Blood · October 1, 1992 Previous studies of risk factors for acute graft-versus-host disease (GVHD) involved patients receiving predominantly single-agent prophylaxis. Therefore, a retrospective analysis was performed on 446 patients, from a single institution, who received trans ... Link to item Cite

Etoposide, cyclophosphamide and fractionated total body irradiation as a preparative regimen for marrow transplantation in patients with advanced hematological malignancies: a phase I study.

Journal Article Bone Marrow Transplant · July 1992 Featured Publication Thirty-seven patients with advanced hematologic malignancy were entered into a phase I study designed to define a maximum tolerable dose (MTD) of etoposide (VP-16) and cyclophosphamide (CY) combined with 12 Gy fractionated total body irradiation (TBI) as p ... Link to item Cite

Immunosuppressive therapy of aplastic anemia: results of a prospective, randomized trial of antithymocyte globulin (ATG), methylprednisolone, and oxymetholone to ATG, very high-dose methylprednisolone, and oxymetholone.

Journal Article Blood · May 15, 1992 Sixty-eight patients with moderate (n = 15) or severe (n = 53) aplastic anemia were entered into a prospective, randomized, two-arm treatment study comparing antihuman thymocyte globulin (ATG), lower-dose methylprednisolone (LDM) and oxymetholone to ATG, h ... Link to item Cite

Phase II trial of recombinant human granulocyte-macrophage colony-stimulating factor in patients undergoing allogeneic bone marrow transplantation from unrelated donors.

Journal Article Blood · May 15, 1992 The safety and possible efficacy of recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) were evaluated in 40 consecutive patients who received transplants from unrelated donors. rhGM-CSF was administered by 2-hour daily intravenou ... Link to item Cite

Ursodeoxycholic acid treatment of refractory chronic graft-versus-host disease of the liver.

Journal Article Ann Intern Med · April 15, 1992 Featured Publication OBJECTIVE: To determine the safety and efficacy of ursodeoxycholic acid treatment in patients with chronic graft-versus-host disease (GVHD) of the liver. DESIGN: Open-label study in which each patient served as his or her own control. SETTING: Private prac ... Full text Link to item Cite

Marrow transplantation for Fanconi anemia with or without leukemic transformation: an update of the Seattle experience.

Journal Article Bone Marrow Transplant · March 1992 Featured Publication Between March 1973 and August 1990, 17 patients with Fanconi anemia (FA) underwent bone marrow transplantation in Seattle. Marrow donors were HLA identical siblings (n = 14), phenotypically HLA identical parents (n = 2) and a one antigen mismatched parent ... Link to item Cite

Mixed leukocyte culture reactivity and graft-versus-host disease in HLA-identical marrow transplantation for leukemia.

Journal Article Bone Marrow Transplant · February 1992 Featured Publication The results of pretransplant mixed leukocyte culture (MLC) assays were compared to subsequent risk of graft-versus-host disease (GVHD) in 783 patients receiving marrow transplants from HLA genotypically identical sibling donors. The mean MLC response obser ... Link to item Cite

Clinical experience with Tc-99m labeled (N2S2) anti-melanoma antibody fragments and single photon emission computed tomography.

Journal Article Am J Physiol Imaging · 1992 We evaluated the imaging capability of murine Tc-99m-labeled antimelanoma Fab fragments in 12 patients with clinical stage II and III melanoma. Tc-99m-NRX118.7 antimelanoma Fab fragment, 10.0 to 27.2 mCi (370-1, 006 MBq), was injected IV 30 min after irrel ... Link to item Cite

Late complications of allogeneic and autologous marrow transplantation.

Journal Article Bone Marrow Transplant · 1992 Featured Publication Link to item Cite

Marrow transplantation following escalating doses of fractionated total body irradiation and cyclophosphamide--a phase I trial.

Journal Article Int J Radiat Oncol Biol Phys · 1992 Featured Publication Thirty-six patients with advanced hematologic malignancy were entered into a Phase I study designed to define the maximum tolerated dose of unshielded total body irradiation delivered from dual 60 Cobalt sources at an exposure rate of 8 cGy/min and given i ... Full text Link to item Cite

Photoinactivation of lymphohemopoietic cells: studies in transfusion medicine and bone marrow transplantation.

Journal Article Blood Cells · 1992 Featured Publication Ultraviolet (UV) irradiation affects eukaryotic cells in numerous ways. Exposure of blood transfusion products to UVC (200-280 nm) or UVB (280-320 nm) reduces or abrogates their immunogenicity and thereby prevents allosensitization and transfusion refracto ... Link to item Cite

A pilot study of low-dose cyclosporin for graft-versus-host prophylaxis in marrow transplantation.

Journal Article Br J Haematol · January 1992 Nineteen patients with leukaemia, preleukaemia, and aplastic anaemia were treated by marrow transplantation from HLA-identical siblings. All were given postgrafting immunosuppression with a combination of methotrexate (days 1, 3, 6 and 11) and cyclosporin ... Full text Link to item Cite

Busulfan and cyclophosphamide as a preparative regimen for bone marrow transplantation in patients with prior chest radiotherapy.

Journal Article Bone Marrow Transplant · September 1991 Featured Publication In a previous study, we reported that patients with hematologic malignancies who had received prior chest radiotherapy had a 32% risk of developing fatal interstitial pneumonia (IP) when prepared for bone marrow transplantation (BMT) with a regimen contain ... Link to item Cite

Treatment of adult acute lymphoblastic leukemia with allogeneic bone marrow transplantation. Multivariate analysis of factors affecting acute graft-versus-host disease, relapse, and relapse-free survival.

Journal Article Bone Marrow Transplant · June 1991 Between February 1972 and December 1987, 192 adults (greater than or equal to 18 years old) with acute lymphoblastic leukemia were transplanted using genotypically HLA-identical marrow donors. Median patient age was 23 years. Eighty-nine patients were in m ... Link to item Cite

Prophylaxis of graft-versus-host disease by administration of the murine anti-IL-2 receptor antibody 2A3.

Journal Article Bone Marrow Transplant · May 1991 The efficacy of murine monoclonal IgG1 antibody 2A3 specific for the 55 kD chain of the human IL-2 receptor (CD25) was evaluated for prophylaxis of acute GVHD in patients with advanced leukemia transplanted with unmodified bone marrow from related HLA-hapl ... Link to item Cite

Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: a randomized trial of two irradiation regimens.

Journal Article Blood · April 15, 1991 A randomized trial was performed to compare two regimens of total body irradiation in patients with chronic myeloid leukemia treated by allogeneic marrow transplantation while in the chronic phase. All patients received cyclophosphamide 120 mg/kg followed ... Link to item Cite

Transfusions shortly before HLA-matched marrow transplantation for leukemia are associated with a decrease in chronic graft-versus-host disease.

Journal Article Bone Marrow Transplant · April 1991 Featured Publication The effect of random red cell transfusions given shortly before allogeneic bone marrow transplantation (BMT) was evaluated in 969 leukemic patients transplanted from an HLA-identical sibling donor. Patients were divided into two groups: 501 who received a ... Link to item Cite

Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies.

Journal Article Transplantation · February 1991 Less than 40% of the patients who could benefit from marrow transplantation have an HLA-matched relative who can serve as a donor. For this reason, several centers have explored marrow transplantation from other categories of donors. This retrospective stu ... Full text Link to item Cite

Long-term follow-up of patients who received recombinant human granulocyte-macrophage colony stimulating factor after autologous bone marrow transplantation for lymphoid malignancy.

Journal Article Bone Marrow Transplant · January 1991 Featured Publication Twenty-seven patients with lymphoid neoplasia who underwent autologous bone marrow transplant (BMT) and who had received recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) were followed in order to examine the potential long-term ... Link to item Cite

Intravenous IgG to prevent graft-versus-host disease after bone marrow transplantation (Reply)

Journal Article New England Journal of Medicine · January 1, 1991 Cite

Staging non-small cell carcinoma of the lung using technetium-99m-labeled monoclonal antibodies.

Journal Article Hematol Oncol Clin North Am · December 1990 A technetium-labeled monoclonal antibody was administered to 52 patients with non-small cell lung carcinoma, either to stage the mediastinum preoperatively or to detect distant metastases. Results from planar and tomographic imaging are compared to CT and ... Link to item Cite

Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens.

Journal Article Blood · November 1, 1990 A randomized trial of 12.0 Gy versus 15.75 Gy of total body irradiation (TBI) was performed in patients with acute myeloid leukemia undergoing allogeneic marrow transplantation while in first complete remission. All patients received 120 mg/kg cyclophospha ... Link to item Cite

A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment.

Journal Article Blood · October 15, 1990 We have reviewed results of therapy in 740 patients with grades II-IV acute graft-versus-host disease (GVHD) after allogeneic marrow transplantation. At the beginning of therapy, 597 patients (81%) had rash, 369 (50%) had liver dysfunction and 396 (54%) ha ... Link to item Cite

Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation.

Journal Article N Engl J Med · September 13, 1990 Featured Publication BACKGROUND: Graft-versus-host disease (GVHD) and infection are major complications of allogeneic bone marrow transplantation. Since intravenous immunoglobulin has shown benefit in several immunodeficiency and autoimmune disorders, we studied its antimicrob ... Full text Link to item Cite

What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants?

Journal Article Blood · September 1, 1990 Featured Publication One hundred forty-seven consecutive patients with leukemia, myelodysplastic syndrome, or aplastic anemia were treated by marrow grafts from genotypically HLA-identical siblings (n = 122) or HLA-haploidentical family members (n = 25). Haploidentical recipie ... Link to item Cite

Value of day 100 screening studies for predicting the development of chronic graft-versus-host disease after allogeneic bone marrow transplantation.

Journal Article Blood · July 1, 1990 We prospectively evaluated 169 patients with a number of screening studies performed between 71 to 121 days after allogeneic marrow transplantation to detect the development of chronic graft-versus-host disease (GVHD). Group 1 patients (n = 78) were asympt ... Link to item Cite

A phase I-II study evaluating the murine anti-IL-2 receptor antibody 2A3 for treatment of acute graft-versus-host disease.

Journal Article Transplantation · July 1990 A murine IgG1 antibody specific for the IL-2-binding site on the human lymphocyte IL-2 receptor beta chain (CD25) was evaluated in 11 patients who developed acute graft-versus-host disease following allogeneic marrow transplantation. All patients had recei ... Full text Link to item Cite

Prevalence of nutrition-related problems among long-term survivors of allogeneic marrow transplantation.

Journal Article J Am Diet Assoc · June 1990 Featured Publication The nutritional status and prevalence of nutrition-related problems in 192 adult and child allogeneic marrow transplant recipients were evaluated 1 year after transplant in a retrospective chart review. Among these patients, 63% exhibited evidence of chron ... Link to item Cite

Gynecological abnormalities following allogeneic bone marrow transplantation.

Journal Article Bone Marrow Transplant · June 1990 Forty-four post-pubertal women were studied 261-4628 days after allogeneic transplantation to determine the nature and degree of gynecological abnormalities following bone marrow transplantation. Evaluations included pelvic examinations, exfoliative cytolo ... Link to item Cite

Bone marrow transplantation for patients with myelodysplasia. Pretreatment variables and outcome.

Journal Article Ann Intern Med · April 15, 1990 STUDY OBJECTIVE: To determine the efficacy of allogeneic bone marrow transplantation for severe myelodysplasia, and to identify variables predictive of outcome. DESIGN: Case series study. SETTING: A referral-based bone marrow transplant center. PATIENTS: C ... Full text Link to item Cite

Autologous marrow transplantation for malignant lymphoma: a report of 101 cases from Seattle.

Journal Article J Clin Oncol · April 1990 Featured Publication Between October 1979 and January 1988, 101 patients with malignant lymphoma who failed initial induction treatment or relapsed received high-dose combination chemotherapy or chemoradiotherapy followed by infusion of autologous bone marrow. Twenty-eight of ... Full text Link to item Cite

Previous donor pregnancy as a risk factor for acute graft-versus-host disease in patients with aplastic anaemia treated by allogeneic marrow transplantation.

Journal Article Br J Haematol · April 1990 Featured Publication To determine if previous donor pregnancies influence the development of acute graft-versus-host disease (GVHD) we evaluated data from 136 patients with aplastic anaemia greater than 15 years of age and given marrow grafts from HLA-identical sibling donors. ... Full text Link to item Cite

Self-administration of morphine in bone marrow transplant patients reduces drug requirement.

Journal Article Pain · February 1990 Featured Publication Bone marrow transplant recipients were randomly assigned to receive morphine by either continuous infusion (32 patients) or self-administration of small boluses (patient-controlled analgesia (PCA), 26 patients) for control of chemoradiotherapy-induced oral ... Full text Link to item Cite

Recognition, incidence, and management of oral graft-versus-host disease.

Journal Article NCI Monogr · 1990 Featured Publication Acute and chronic graft-versus-host disease (GVHD) are significant complications of allogeneic bone marrow transplantation that occur when immunologically active T-cell lymphocytes are transplanted into an immunosuppressed recipient who is genetically disp ... Link to item Cite

Supportive care of the marrow transplant recipient: the Seattle Experience.

Journal Article Haematol Blood Transfus · 1990 Featured Publication It is now almost 2 decades after the first successful human marrow transplants from HLA-identical siblings for the treatment of life-threatening hematologic diseases. Results have improved, especially for patients transplanted earlier in the course of dise ... Full text Link to item Cite

Chronic graft-versus-host disease.

Journal Article Cancer Treat Res · 1990 Featured Publication Full text Link to item Cite

HLA-identical transplantation in the leukemias without T-cell depletion

Journal Article Bone Marrow Transplantation · 1990 Cite

Long term effects and quality of life in children and adults after marrow transplantation.

Journal Article Bone Marrow Transplant · December 1989 These studies of late effects associated with marrow transplant preparative regimens demonstrate the need for continued long-term follow-up of these patients. Sequential studies of growth and development in children demonstrate that few endocrine function ... Link to item Cite

Minimal risk of chronic renal dysfunction in marrow transplant recipients treated with cyclosporine for 6 months.

Journal Article Bone Marrow Transplant · November 1989 To determine whether 6 months of cyclosporine therapy is associated with chronic renal dysfunction, we evaluated serum creatinine concentrations 1 year post-transplant in 82 marrow transplant recipients randomized to receive either cyclosporine (n = 40) or ... Link to item Cite

Busulfan, cyclophosphamide and fractionated total body irradiation as a preparatory regimen for marrow transplantation in patients with advanced hematological malignancies: a phase I study.

Journal Article Bone Marrow Transplant · November 1989 Thirty-six patients with advanced hematologic malignancy were entered into a phase I study designed to define a tolerable dose of busulfan (BU) and cyclophosphamide (CY) combined with 12 Gy of fractionated total body irradiation (TBI) as preparation for ma ... Link to item Cite

Intravenous immune globulin prophylaxis in recipients of a marrow transplant.

Journal Article J Allergy Clin Immunol · October 1989 Featured Publication Bone marrow transplantation is a worldwide activity involving more than 250 transplant centers in more than 40 countries. The ultimate success of the procedure depends in large measure on supportive care of the transplant recipient. A major component of th ... Full text Link to item Cite

Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia.

Journal Article N Engl J Med · September 21, 1989 To determine the incidence of secondary cancers after bone marrow transplantation, we reviewed the records of all patients at our center who received allogeneic, syngeneic, or autologous transplants for leukemia (n = 1926) or aplastic anemia (n = 320). Thi ... Full text Link to item Cite

Regimen-related toxicity and early posttransplant survival in patients undergoing marrow transplantation for lymphoma.

Journal Article J Clin Oncol · September 1989 Ninety-five patients transplanted for malignant lymphoma were retrospectively evaluated for regimen-related toxicity (RRT) and early posttransplant survival. Nineteen patients developed life-threatening (grade 3) or fatal (grade 4) RRT in one or more organ ... Full text Link to item Cite

High-dose cytosine arabinoside, total body irradiation and marrow transplantation for advanced malignant lymphoma.

Journal Article Bone Marrow Transplant · September 1989 Twenty-four patients with advanced malignant lymphoma including Hodgkin's disease (HD, n = 1), intermediate grade non-Hodgkin's lymphoma (IGL, n = 12) and high-grade non-Hodgkin's lymphoma (HGL, n = 11) were prepared for syngeneic (n = 2), allogeneic (n = ... Link to item Cite

Obstructive lung disease after allogeneic marrow transplantation. Clinical presentation and course.

Journal Article Ann Intern Med · September 1, 1989 To describe the clinical presentation and progression of obstructive lung disease after marrow transplantation, we examined a sequential sample of 35 patients who had allogeneic marrow transplantation between January 1980 and January 1987, were 16 years or ... Full text Link to item Cite

Graft-versus-host disease prevention by methotrexate combined with cyclosporin compared to methotrexate alone in patients given marrow grafts for severe aplastic anaemia: long-term follow-up of a controlled trial.

Journal Article Br J Haematol · August 1989 Forty-six patients with aplastic anaemia (median age 23 years) were given cyclophosphamide followed by infusion of marrow from an HLA-identical family member. To evaluate postgrafting prophylaxis for graft-versus-host disease (GVHD), the patients were ente ... Full text Link to item Cite

Current status of bone marrow transplantation.

Journal Article Transplant Proc · June 1989 Link to item Cite

Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia.

Journal Article Blood · May 1, 1989 Featured Publication To assess the influence of graft-versus-host disease (GVHD) on recurrent leukemia and survival after allogeneic marrow transplantation, we studied 1,202 patients with acute nonlymphocytic leukemia (ANL), acute lymphocytic leukemia (ALL), and chronic myelog ... Link to item Cite

Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms.

Journal Article N Engl J Med · March 30, 1989 Featured Publication The occurrence of graft-versus-host disease (GVHD) after allogeneic bone marrow transplantation for leukemia is thought to decrease the probability of recurrence. To study this effect (called adoptive immunotherapy) we modified the prophylaxis of GVHD in p ... Full text Link to item Cite

Assessment and management of donor pain following marrow harvest for allogeneic bone marrow transplantation.

Journal Article Bone Marrow Transplant · March 1989 Featured Publication We studied the time course and intensity of pain of multiple bone marrow aspirations in 30 healthy adult marrow donors receiving acetaminophen with codeine for analgesia immediately after marrow harvesting for allogeneic bone marrow transplantation. Upon d ... Link to item Cite

Chemoradiotherapy toxicity during bone marrow transplantation: time course and variation in pain and nausea.

Journal Article Bone Marrow Transplant · March 1989 Featured Publication Chemoradiotherapy-induced toxicity following unmodified allogeneic marrow grafting was studied. Patients with hematologic malignancy (n = 157) received cyclophosphamide (120 mg/kg) followed by single or fractionated total body irradiation (TBI); aplastic a ... Link to item Cite

Factors predicting chronic graft-versus-host disease and survival after marrow transplantation for aplastic anemia.

Journal Article Bone Marrow Transplant · March 1989 The cumulative incidence of chronic graft-versus-host disease (GVHD) was 48% among 165 patients with severe aplastic anemia who had been discharged from Seattle 3 months after they were treated with marrow grafts from HLA-identical siblings. Estimated 10-y ... Link to item Cite

Graft-v-host disease is associated with autoimmune-like thrombocytopenia.

Journal Article Blood · March 1989 Persistent thrombocytopenia after allogeneic marrow transplantation is associated with poor patient survival. To identify the mechanisms of the thrombocytopenia, we studied platelet and fibrinogen kinetics and antiplatelet antibodies in 20 patients between ... Link to item Cite

Congress review: progress and prospects in bone marrow transplantation.

Journal Article Transplant Proc · February 1989 Featured Publication Link to item Cite

Long-term results of allogeneic bone marrow transplantation.

Journal Article Transplant Proc · February 1989 Featured Publication Link to item Cite

Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma.

Journal Article N Engl J Med · January 26, 1989 We analyzed the relevance of HLA compatibility to sustained marrow engraftment in 269 patients with hematologic neoplasms who underwent bone marrow transplantations. Each patient received marrow from a family member who shared one HLA haplotype with the pa ... Full text Link to item Cite

Marrow transplantation for malignant plasma cell disorders: summary of the Seattle experience.

Journal Article Eur J Haematol Suppl · 1989 28 patients with plasma cell malignancies received marrow transplants from identical twins (N = 8), HLA-identical family members (N = 15), HLA partially-matched relatives (N = 3) or cryopreserved autologous marrow (N = 2). Treatment regimens included cyclo ... Full text Link to item Cite

Intravenous immune globulin prophylaxis in recipients of a marrow transplant

Journal Article The Journal of Allergy and Clinical Immunology · 1989 Bone marrow transplantation is a worldwide activity involving more than 250 transplant centers in more than 40 countries.1 The ultimate success of the procedure depends in large measure on supportive care of the transplant recipient. A major component of t ... Cite

Intravenous immune globulin prophylaxis in recipients of a marrow transplant

Journal Article Journal of Allergy and Clinical Immunology · January 1, 1989 Bone marrow transplantation is a worldwide activity involving more than 250 transplant centers in more than 40 countries. The ultimate success of the procedure depends in large measure on supportive care of the transplant recipient. A major component of th ... Cite

Deletion of immunosuppressive prophylaxis after marrow transplantation increases hyperacute graft-versus-host disease but does not influence chronic graft-versus-host disease or relapse in patients with advanced leukemia

Journal Article Clinical Transplantation · January 1, 1989 Sixteen patients < 30 years of age with advanced leukemia who were given unmodified marrow grafts from HLA-identical siblings without posttransplant immunosuppression were compared to 44 age- and disease-matched controls who received methotrexate (MTX) to ... Cite

Marrow transplantation for malignant plasma cell disorders: Summary of the Seattle experience

Journal Article European Journal of Haematology, Supplement · 1989 28 patients with plasma cell malignancies received marrow transplants from identical twins(N = 8), HLA-identical family members (N = 15), HLA partially-matched relatives (N = 3) or cryopreserved autologous marrow (N = 2). Treatment regimens included cyclop ... Cite

Congress review: Progress and prospects in bone marrow transplantation

Journal Article Transplantation Proceedings · January 1, 1989 Cite

Engraftment in 86 with patients lymphoid malignancy after autologous marrow transplantation.

Journal Article Bone Marrow Transplant · January 1989 The kinetics of marrow engraftment was retrospectively analysed in 55 patients with malignant lymphoma (ML) and 31 patients with acute lymphoblastic leukemia (ALL) after marrow-ablative therapy followed by autologous bone marrow transplantation. Thirty-eig ... Link to item Cite

Long-term results of allogeneic bone marrow transplantation

Journal Article Transplantation Proceedings · January 1, 1989 Cite

HLA-identical marrow transplantation during accelerated-phase chronic myelogenous leukemia: analysis of survival and remission duration.

Journal Article Blood · December 1988 Results of HLA-identical allogeneic marrow transplantation were analyzed for 66 patients with accelerated-phase chronic myelogenous leukemia (CML). Multivariate proportional hazards regression models were used to determine disease-related and transplant-re ... Link to item Cite

Graft failure in patients receiving T cell-depleted HLA-identical allogeneic marrow transplants.

Journal Article Bone Marrow Transplant · September 1988 Results of a previous study suggested that the risk of graft failure after transplantation of HLA-identical T cell-depleted marrow may be influenced by the preparative regimen. Subsequent clinical trials were carried out to clarify this relationship and to ... Link to item Cite

Transfer of specific immunity in marrow recipients given HLA-mismatched, T cell-depleted, or HLA-identical marrow grafts.

Journal Article Bone Marrow Transplant · September 1988 The transfer of tetanus toxoid (TT) and diphtheria toxoid (DT) specific immunity was evaluated in 209 short-term (less than 120 days postgrafting) and 257 long-term (greater than 198 days postgrafting) non-boosted recipients after HLA-identical, HLA non-id ... Link to item Cite

Use of thymic grafts or thymic factors to augment immunologic recovery after bone marrow transplantation: brief report with 2 to 12 years' follow-up.

Journal Article Bone Marrow Transplant · September 1988 Thymus tissue implants, thymic epithelial cells obtained from third party donors sharing one HLA-A and -B locus with the recipient, or the thymic hormones thymosin fraction 5 and thymopentin were given to recipients of HLA-identical sibling bone marrow to ... Link to item Cite

Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation.

Journal Article Blood · August 1988 We conducted a randomized, double-blind comparison of prednisone and placebo (group I) v prednisone and azathioprine (1.5 mg/kg/day) (group II) as early treatment of extensive chronic graft-v-host disease (GVHD). Patients with platelet counts less than 100 ... Link to item Cite

Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease.

Journal Article Blood · August 1988 Therapy of chronic graft-v-host disease (GVHD) has been unsatisfactory in patients with platelet counts less than 100,000/microL. Survival at 5 years after marrow transplant is only 26% in such patients treated with trimethoprim-sulfamethoxazole (TMP-SMX) ... Link to item Cite

Ovarian function following marrow transplantation for aplastic anemia or leukemia.

Journal Article J Clin Oncol · May 1988 One hundred eighty-seven women between 13 and 49 years of age had ovarian function evaluated from 1 to 15 years (median, 4) after marrow transplant for aplastic anemia or leukemia. Among 43 women transplanted for aplastic anemia following 200 mg/kg cycloph ... Full text Link to item Cite

Allogeneic marrow transplantation for children with juvenile chronic myelogenous leukemia.

Journal Article Blood · April 1988 Fourteen children between the ages of 2 and 5 years with juvenile chronic myelogenous leukemia were given cyclophosphamide, total-body irradiation, and marrow transplants. Unmodified marrow was given to six patients who received marrow from HLA-identical s ... Link to item Cite

High-dose cytarabine and total body irradiation with or without cyclophosphamide as a preparative regimen for marrow transplantation for acute leukemia.

Journal Article J Clin Oncol · April 1988 Twenty-nine patients were conditioned for allogeneic marrow transplant with cytarabine (ara-C) (3 g/m2 every 12 hours for 12 doses) and total body irradiation (TBI) (200 cGy daily for six days) with or without cyclophosphamide (CY) (60 mg/kg) to determine ... Full text Link to item Cite

Cyclosporine v methotrexate for graft-v-host disease prevention in patients given marrow grafts for leukemia: long-term follow-up of three controlled trials.

Journal Article Blood · February 1988 One hundred seventy-nine patients with acute nonlymphoblastic leukemia in first remission (n = 75), chronic myelocytic leukemia in chronic or accelerated phase (n = 48) or leukemia in advanced stage (n = 56) were given HLA-identical marrow grafts and rando ... Link to item Cite

Second marrow transplants in patients with leukemia who relapse after allogeneic marrow transplantation.

Journal Article Bone Marrow Transplant · January 1988 Twenty-six patients with recurrent leukemia following allogeneic marrow transplantation received a second marrow transplant between 1.5 and 78 months (median 26) after the initial transplant. Preparative regimens for second transplant included multi-agent ... Link to item Cite

Predictive facts and prevention of acute graft-versus-host disease: The Seattle experience

Journal Article Bone Marrow Transplantation · January 1, 1988 Cite

Marrow transplantation for patients with acute lymphoblastic leukemia in first marrow remission.

Journal Article Bone Marrow Transplant · December 1987 Forty-six patients with acute lymphoblastic leukemia (ALL) in first marrow remission underwent allogeneic marrow transplantation between August 1976 and June 1985. Thirty-four patients had no extramedullary disease after remission induction and 12 had extr ... Link to item Cite

Prophylactic use of human leukocyte interferon after allogeneic marrow transplantation.

Journal Article Ann Intern Med · December 1987 STUDY OBJECTIVE: To determine the efficacy of prophylactic interferon for prevention of cytomegalovirus infection and relapse of leukemia after allogeneic marrow transplantation. DESIGN: Randomized trial with intermittent interferon administration to day 8 ... Full text Link to item Cite

Risk factors for airflow obstruction in recipients of bone marrow transplants.

Journal Article Ann Intern Med · November 1987 Obstructive lung disease is a complication of bone marrow transplantation. To identify risk factors we analyzed pulmonary function tests of 281 adult patients 1 year after marrow transplantation. The forced expiratory volume at 1 second divided by the forc ... Full text Link to item Cite

Immunoglobulin therapy in bone marrow transplantation.

Journal Article Am J Med · October 23, 1987 Following ablative treatment with supralethal doses of chemotherapy and total body irradiation, patients demonstrate multiple immunologic deficiencies after bone marrow transplantation. Immune function usually recovers and the risk of infection decreases w ... Full text Link to item Cite

The treatment of acute non-lymphoblastic leukemia by allogeneic marrow transplantation.

Journal Article Bone Marrow Transplant · October 1987 The results are presented of allogeneic transplantation for 363 patients with acute non-lymphoblastic leukemia treated in Seattle from May 1973 through December 1985. The probabilities of surviving disease-free for 5 years for patients transplanted in firs ... Link to item Cite

Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation, and marrow transplantation.

Journal Article J Clin Oncol · September 1987 Between July 1970 and January 1985, 100 patients with malignant lymphoma were treated with high-dose chemoradiotherapy and bone marrow transplantation. Twenty-eight of the 100 are alive and the actuarial probability of disease-free survival 5 years from tr ... Full text Link to item Cite

The effect of prophylactic intravenous immune globulin on the incidence of septicemia in marrow transplant recipients.

Journal Article Bone Marrow Transplant · August 1987 Ninety-seven patients randomized to receive (45 patients) or not to receive (52 patients) intravenous cytomegalovirus immune globulin before and after allogeneic marrow transplantation were evaluated retrospectively for the occurrence of bacterial and fung ... Link to item Cite

Second marrow transplants in patients with aplastic anemia rejecting the first graft: use of a conditioning regimen including cyclophosphamide and antithymocyte globulin.

Journal Article Blood · July 1987 Sixteen (11%) of 146 consecutive patients with severe aplastic anemia prepared for engraftment with cyclophosphamide (200 mg/kg) rejected marrow grafts from their HLA-identical siblings. They were given a second marrow transplant from either the same (n = ... Link to item Cite

Marrow transplantation for acute nonlymphocytic leukemia following therapy for Hodgkin's disease.

Journal Article J Clin Oncol · May 1987 Seven patients with acute nonlymphocytic leukemia (ANL) following therapy for Hodgkin's disease (HD) were treated with cyclophosphamide (Cy) alone or combined with 10.00 to 15.75 Gy total body irradiation (TBI) and marrow transplantation. Five patients wer ... Full text Link to item Cite

Direct ultrastructural evidence of target-directed polarization by cytotoxic lymphocytes in lesions of human graft-vs-host disease.

Journal Article Arch Pathol Lab Med · April 1987 Cytotoxic lymphocytes are thought to kill target cells by means of potent cytotoxic granules that congregate near the microtubular organizing center and the Golgi apparatus at one pole of the killer cell. We searched for evidence of this type of polarizati ... Link to item Cite

Treatment of marrow graft recipients with thymopentin.

Journal Article Bone Marrow Transplant · April 1987 Four adult patients with acute non-lymphocytic leukemia were given marrow grafts from HLA-identical siblings following 120 mg/kg cyclophosphamide and 10-12 Gy total body irradiation. All received intermittent intravenous methotrexate as prophylaxis against ... Link to item Cite

Treatment of aplastic anemia with antithymocyte globulin, high-dose corticosteroids, and androgens.

Journal Article Exp Hematol · March 1987 A total of 46 patients with aplastic anemia (34 severe; 12 moderate) were treated with antihuman thymocyte globulin (ATG), high-dose methylprednisolone, and oxymetholone. Early symptoms of ATG toxicity included fever, rash, and bronchospasm. Signs of serum ... Link to item Cite

Adoptively transferred immunity persists in human marrow graft recipients.

Journal Article Prog Clin Biol Res · 1987 This study was designed to determine if antibodies (Abs) to recall antigens (Ags) were produced after bone marrow transplantation (BMT). Sera from marrow recipients (recipients) were tested for Abs to recall Ags post-grafting, and T and B cells from recipi ... Link to item Cite

Graft versus leukemia effect in man: the relapse rate of acute leukemia is lower after allogeneic than after syngeneic marrow transplantation.

Journal Article Prog Clin Biol Res · 1987 To determine whether allogeneic bone marrow transplantation (BMT) is associated with a graft vs leukemia (GVL) effect in man, the relapse rate of acute leukemia after allogeneic BMT was compared with that occurring after syngeneic (genetically identical tw ... Link to item Cite

Graft-versus-leukemia in man: relationship of acute and chronic graft-versus-host disease to relapse of acute leukemia following allogeneic bone marrow transplantation.

Journal Article Prog Clin Biol Res · 1987 To study the effect of acute and chronic graft-versus-host disease (GVHD) on recurrent leukemia, we analysed data on patients with acute leukemia receiving allogeneic marrow transplants in Seattle between 1970 and 1986. Four hundred fifty-four patients sur ... Link to item Cite

Marrow transplantation for acute nonlymphoblastic leukemia in first remission: toxicity and long-term follow-up of patients conditioned with single dose or fractionated total body irradiation.

Journal Article Bone Marrow Transplant · December 1986 Seventy-five patients with acute nonlymphoblastic leukemia (ANL) in first remission were treated with cyclophosphamide, 60 mg/kg on each of two consecutive days followed by total body irradiation (TBI) at an exposure rate of 4-6 cGy/min from two opposing 6 ... Link to item Cite

Decreased incidence of marrow graft rejection in patients with severe aplastic anemia: changing impact of risk factors.

Journal Article Blood · December 1986 Patients with severe aplastic anemia were conditioned with cyclophosphamide (200 mg/kg) and given marrow grafts from HLA-identical family members. Among 233 patients transplanted, 225 survived greater than or equal to 14 days and could be evaluated for eng ... Link to item Cite

Growth and development following marrow transplantation for leukemia.

Journal Article Blood · November 1986 One hundred forty-two patients between the ages of 1 and 17 years who survived disease-free more than 1 year after marrow transplantation for hematologic malignancy had growth and development evaluations from one to 14 years posttransplant (median 4 years) ... Link to item Cite

Myasthenia gravis after allogeneic bone marrow transplantation: relationship to chronic graft-versus-host disease.

Journal Article Neurology · August 1986 Three patients with chronic graft-versus-host disease (GVHD) developed myasthenia gravis (MG) 762 to 1,180 days after allogeneic bone marrow transplantation. Symptoms of MG were observed after taper or discontinuation of immunosuppressive treatment of chro ... Full text Link to item Cite

Second marrow infusion for poor graft function after allogeneic marrow transplantation.

Journal Article Bone Marrow Transplant · May 1986 Fifty-seven patients undergoing allogeneic marrow transplantation had persistent poor graft function after transplant and received a second marrow infusion from the original donor. Eight donors were HLA-non-identical family members and 49 were HLA-identica ... Link to item Cite

Severe aplastic anemia associated with chronic mucocutaneous candidiasis. Immunologic and hematologic reconstitution after allogeneic bone marrow transplantation.

Journal Article Transplantation · May 1986 Chronic mucocutaneous candidiasis (CMC) is typically associated with the inability of T lymphocytes to proliferate and produce lymphokines in response to Candida antigen. A 7-year-old girl with CMC developed severe aplastic anemia and, after conditioning w ... Full text Link to item Cite

Hyperacute graft-v-host disease in patients not given immunosuppression after allogeneic marrow transplantation.

Journal Article Blood · April 1986 Sixteen patients with leukemia in relapse or second to third remission, 5 to 27 years old (median, 17), were given cyclophosphamide (60 mg/kg X 2) and total body irradiation (2.25 Gy for each of seven days) followed by unmodified marrow grafts from HLA-ide ... Link to item Cite

Marrow transplantation for severe aplastic anemia. Long-term outcome in fifty "untransfused" patients.

Journal Article Ann Intern Med · April 1986 Fifty patients with severe aplastic anemia had no transfusions of blood products until just before marrow transplantation from HLA-identical family members. Of the 50, 42 are still alive 1 to 12 years after transplantation (median, 7 years). By actuarial s ... Full text Link to item Cite

Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia.

Journal Article N Engl J Med · March 20, 1986 We treated 93 patients who had acute nonlymphoblastic leukemia in the first remission or chronic myelocytic leukemia in the chronic phase (median age, 30 years) with high-dose cyclophosphamide and fractionated total-body irradiation, followed by infusion o ... Full text Link to item Cite

Bone marrow transplantation in patients aged 45 years and older.

Journal Article Blood · March 1986 Increasing age has been reported to be a poor prognostic factor for survival after bone marrow transplantation. We evaluated causes of death and frequency and type of complications after marrow grafting in 24 syngeneic and 39 allogeneic recipients who were ... Link to item Cite

Acute and chronic graft-versus-host disease in man

Journal Article International Journal of Cell Cloning · 1986 Allogeneic bone marrow transplantation offers the hope of cure of heretofore untreatable diseases. Graft-versus-host disease is a complication of this medical progress and impedes application of marrow grafting to a wider range of hematologic disorders. It ... Cite

Early and late interstitial pneumonia following human bone marrow transplantation.

Journal Article Int J Cell Cloning · 1986 Interstitial pneumonia is a major determinant of early and late morbidity and mortality following bone marrow transplantation. Among 952 patients receiving allogeneic marrow grafts in Seattle, 35% developed interstitial pneumonia within 100 days of transpl ... Full text Link to item Cite

Antithymocyte globulin followed by cyclosporine for the treatment of acute GVHD in patients given HLA-identical or -nonidentical marrow grafts

Journal Article Transplantation Proceedings · January 1, 1986 Graft-v-host disease (GVHD) remains a major complication after allogeneic marrow transplantation. Between 30% and 60% of patients given unmanipulated marrow from an HLA-identical sibling donor and 80% of patients transplanted from an HLA-nonidentical donor ... Cite

Selection of patients with Hodgkin's disease and non-Hodgkin's lymphoma for bone marrow transplantation.

Journal Article Int J Cell Cloning · 1986 Despite substantial progress in curative therapy of malignant lymphomas, some patients fail current treatment and die of refractory disease. Although Although high-dose chemotherapy and supralethal total body irradiation followed by bone marrow transplanta ... Full text Link to item Cite

Infection with varicella-zoster virus after marrow transplantation.

Journal Article J Infect Dis · December 1985 Infection with varicella-zoster virus (VZV) occurred in 231 (16.6%) of 1,394 patients undergoing marrow transplantation in Seattle, Washington, between 1969 and 1982. The probability of VZV infection was 30% by one year after transplant. Eighty percent of ... Full text Link to item Cite

Allogeneic marrow transplantation in the treatment of MOPP-resistant Hodgkin's disease.

Journal Article J Clin Oncol · November 1985 Eight patients with disseminated Hodgkin's disease resistant to MOPP (mechlorethamine, vincristine, procarbazine, and prednisone) chemotherapy were treated with high-dose chemoradiotherapy and marrow transplantation from an HLA-identical sibling. Two patie ... Full text Link to item Cite

Treatment of human acute graft-versus-host disease with antithymocyte globulin and cyclosporine with or without methylprednisolone.

Journal Article Transplantation · August 1985 Forty-eight patients with hematologic malignancies treated by allogeneic marrow transplantation developed acute graft-versus-host disease (GVHD), grades II-IV, despite prophylaxis with methotrexate. They were treated with a combination of antithymocyte glo ... Full text Link to item Cite

Treatment of acute graft-versus-host disease after allogeneic marrow transplantation. Randomized study comparing corticosteroids and cyclosporine.

Journal Article Am J Med · June 1985 Seventy-seven patients (age 12 to 46 years) who underwent allogeneic marrow transplantation for hematologic malignancy or aplastic anemia and who had grade II to IV acute graft-versus-host disease despite methotrexate prophylaxis were randomly assigned to ... Full text Link to item Cite

Graft versus host disease-related secretory immunoglobulin A deficiency in bone marrow transplant recipients. Findings in labial saliva.

Journal Article Lab Invest · March 1985 Graft versus host disease-dependent decreases in salivary IgA levels were sought in labial gland saliva samples from bone marrow transplant recipients. Transplantation-associated, irradiation-related effects were also present, but these could be avoided if ... Link to item Cite

Marrow transplantation for leukemia following fractionated total body irradiation. A comparative trial of methotrexate and cyclosporine.

Journal Article Leuk Res · 1985 Fifty-six patients, 30-47 yr of age, with leukemia in relapse received allogeneic marrow transplants from HLA-identical siblings. All patients were treated with cyclophosphamide (120 mg/kg) and 7 daily fractions of 2.25 Gy of total body irradiation (TBI) f ... Full text Link to item Cite

Marrow transplant experience in children with acute lymphoblastic leukemia: an analysis of factors associated with survival, relapse, and graft-versus-host disease.

Journal Article Med Pediatr Oncol · 1985 One hundred fourteen children with acute lymphoblastic leukemia were treated with allogeneic marrow transplantation from HLA-identical siblings after conditioning with cyclophosphamide and total body irradiation. Methotrexate was given posttransplantation ... Full text Link to item Cite

Association between cyclosporin neurotoxicity and hypomagnesaemia.

Journal Article Lancet · November 17, 1984 The serum magnesium levels of all 12 allogeneic bone-marrow transplant recipients who experienced the neurotoxic effects of cyclosporin (CyA) were more than two standard deviations below the normal range. The neurological events seemed to segregate into th ... Full text Link to item Cite

Marrow transplantation in hepatitis-associated aplastic anemia.

Journal Article Am J Hematol · October 1984 Seventeen patients who developed aplastic anemia in association with viral hepatitis were transplanted with sibling marrow. Of the 16 HLA-identical recipients, 14 were conditioned with cyclophosphamide, 200 mg/kg, and two received 10 Gy total body irradiat ... Full text Link to item Cite

Marrow harvesting from normal donors.

Journal Article Blood · September 1984 The experience at a single institution in harvesting marrow for allogeneic transplantation on 1,270 occasions from 1,160 normal donors is presented in detail, together with an analysis of all the donor complications. Four donors were less than 2 years old, ... Link to item Cite

Oral manifestations of chronic graft-v-host disease.

Journal Article Arch Intern Med · August 1984 Sixty patients were studied 180 to 500 days after allogeneic marrow transplantation to determine if late oral abnormalities were associated with the presence of chronic graft-v-host disease (GVHD). Lip and intraoral mucosal surfaces were evaluated for colo ... Link to item Cite

Cataracts after total body irradiation and marrow transplantation: a sparing effect of dose fractionation.

Journal Article Int J Radiat Oncol Biol Phys · July 1984 We examined 277 patients, who have been followed for 1 to 12 years after marrow transplantation, for cataract development. In preparation for transplantation, 96 patients with aplastic anemia were conditioned with chemotherapy only, usually cyclophosphamid ... Full text Link to item Cite

Rapidly progressive air-flow obstruction in marrow transplant recipients. Possible association between obliterative bronchiolitis and chronic graft-versus-host disease.

Journal Article Am Rev Respir Dis · April 1984 Severe obstructive airways disease developed in 4 young nonsmoking adults after marrow transplantation. They were free of respiratory disease until symptoms developed 277 to 600 days after transplant. Pulmonary function testing showed that the mean forced ... Link to item Cite

Prophylaxis of infection in patients with aplastic anemia receiving allogeneic marrow transplants.

Journal Article Am J Med · April 1984 One hundred one patients with severe aplastic anemia underwent allogeneic marrow transplantation and received one of three forms of infection prophylaxis: oral nonabsorbable antibiotics and isolation and decontamination in a laminar airflow room (36 patien ... Full text Link to item Cite

Radiographic features of esophageal involvement in chronic graft-vs.-host disease.

Journal Article AJR Am J Roentgenol · March 1984 Chronic graft-vs.-host disease (GVHD) is an important late complication of allogeneic bone-marrow transplantation. It resembles several naturally occurring autoimmune diseases and involves the skin, mouth, eyes, liver, and esophagus. The radiographic findi ... Full text Link to item Cite

Recovery of in vivo cellular immunity after human marrow grafting. Influence of time postgrafting and acute graft-versus-host disease.

Journal Article Transplantation · February 1984 Three hundred thirty-two marrow graft recipients and 241 healthy marrow donors were studied by skin testing with recall and neoantigens. Two hundred thirty patients with leukemia and seventy-eight patients with aplastic anemia received allogeneic HLA-ident ... Full text Link to item Cite

Association between cyclosporin neurotoxicity and hypomagnesaemia

Journal Article Lancet · 1984 The serum magnesium levels of all 12 allogeneic bone-marrow transplant recipients who experienced the neurotoxic effects of cyclosporin (CyA) were more than two standard deviations below the normal range. The neurological events seemed to segregate into th ... Cite

Marrow transplantation for aplastic anemia.

Journal Article Semin Hematol · January 1984 Link to item Cite

Late complications after marrow transplantation.

Journal Article Semin Hematol · January 1984 Link to item Cite

Allogeneic marrow transplantation.

Journal Article Cancer Invest · 1984 After 15 years of clinical investigation, allogeneic marrow transplantation can be considered the treatment of choice for a variety of hematologic and immunologic diseases. This review has focused upon some of the principles, current results, problems, and ... Full text Link to item Cite

Murine monoclonal anti-T cell antibodies for treatment of steroid-resistant acute graft-versus-host disease.

Journal Article Hum Immunol · January 1984 Four different murine monoclonal anti-T cell antibodies were administered to 15 patients with severe steroid resistant graft versus host disease (GVHD) in a phase I clinical trial in order to evaluate feasibility and toxicity. Antibodies 9.6 (IgG2a) and 35 ... Full text Link to item Cite

Factors associated with graft rejection after HLA-identical marrow transplantation for aplastic anaemia.

Journal Article Br J Haematol · December 1983 One hundred and seventy-five consecutive patients with severe aplastic anaemia were given high-dose cyclophosphamide followed by marrow grafts from healthy, HLA-identical family members, and 168 lived long enough to show engraftment. In 38 patients the gra ... Full text Link to item Cite

Mycobacterial infections in marrow transplant patients.

Journal Article Transplantation · November 1983 Bone marrow transplant recipients undergo ablation of host immune defenses with total-body irradiation or high dose chemotherapy, or both. Over a 5.6-year period, mycobacterial infections were observed in 7 of 682 patients with leukemia who received marrow ... Full text Link to item Cite

The pathophysiology and treatment of graft-versus-host disease.

Journal Article Clin Haematol · October 1983 Acute and chronic GVHD remain major impediments to the wider application of allogeneic marrow transplantation. It is presumed that human acute GVHD is analogous to the murine model which is initiated by donor T lymphocytes reacting with recipient 'minor' h ... Full text Link to item Cite

Recombinant leukocyte A interferon for the treatment of serious viral infections after marrow transplant: a phase I study.

Journal Article J Infect Dis · September 1983 Six marrow-transplant patients with serious virus infections (four with cytomegalovirus and two with adenovirus) were treated with recombinant leukocyte alpha interferon at daily doses of 6,000,000-50,000,000 units to determine safety and tolerance. Fever ... Full text Link to item Cite

Late effects on gonadal function of cyclophosphamide, total-body irradiation, and marrow transplantation.

Journal Article Transplantation · September 1983 One hundred thirty-seven patients had gonadal function evaluated 1-11 years after marrow transplantation. All 15 women less than age 26 and three of nine older than age 26 who were treated with 200 mg/kg cyclophosphamide recovered normal gonadotropin level ... Full text Link to item Cite

Ocular manifestations of graft-v-host disease.

Journal Article Arch Ophthalmol · July 1983 Graft-v-host disease is the major complication of bone marrow transplantation for the leukemias and aplastic anemia. In the clinical evaluation of eye problems of patients with acute graft-v-host disease, findings reveal a disease process of keratoconjunct ... Full text Link to item Cite

Combined modality therapy of advanced non-Hodgkin's lymphoma: an analysis of remission duration and survival in 95 patients.

Journal Article Blood · July 1983 Ninety-five patients with advanced non-Hodgkin's lymphoma were treated with four courses of cyclophosphamide, adriamycin, vincristine and prednisone, with or without procarbazine [CHOP(P)] chemotherapy; either 150 rad total body irradiation (for "extensive ... Link to item Cite

Disordered salivary immunoglobulin secretion and sodium transport in human chronic graft-versus-host disease.

Journal Article Transplantation · May 1983 Whole saliva samples and lip biopsies were collected from 12 allogeneic bone marrow transplant recipients who developed extensive chronic graft-versus-host disease (GVHD) and from 10 healthy allogeneic and syngeneic recipients without GVHD. Six of ten biop ... Full text Link to item Cite

Fanconi's anemia treated by allogeneic marrow transplantation.

Journal Article Blood · May 1983 Eight patients with Fanconi's anemia were given cyclophosphamide alone (seven patients) or combined with procarbazine and antithymocyte globulin (one patient) followed by marrow grafts from HLA-identical siblings. All patients had engraftment. Seven develo ... Link to item Cite

Allogeneic marrow transplantation for acute nonlymphoblastic leukemia after first relapse.

Journal Article Blood · May 1983 Sixty-two patients with acute nonlymphoblastic leukemia in first relapse or second remission were treated with allogeneic marrow transplantation from HLA-matched siblings. In 17 patients (group 1), no attempt at reinduction of remission was made prior to t ... Link to item Cite

Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical siblings.

Journal Article Ann Intern Med · April 1983 One hundred ten of 175 patients with aplastic anemia conditioned by cyclophosphamide had sustained engraftment of marrow from human leukocyte antigen (HLA)-identical siblings and lived for more than 6 months. Forty-nine of the 110 patients developed chroni ... Full text Link to item Cite

Marrow transplantation from HLA-identical siblings for treatment of aplastic anemia: is exposure to marrow donor blood products 24 hours before high-dose cyclophosphamide needed for successful engraftment?

Journal Article Blood · April 1983 The present study in patients with aplastic anemia was undertaken to determine whether exposure of recipients to donor blood products 24 hr before preparation with cyclophosphamide (1) enhanced the rate of sustained engraftment of marrow from HLA-identical ... Link to item Cite

Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment.

Journal Article N Engl J Med · February 10, 1983 One hundred thirty patients with severe aplastic anemia were conditioned with cyclophosphamide for transplantation of marrow from HLA-identical siblings. The patients were selected for the present analysis according to the criterion of sustained marrow eng ... Full text Link to item Cite

Treatment of non-Hodgkin's lymphoma with chemoradiotherapy and allogenic marrow transplantation.

Journal Article Hematol Oncol · 1983 Twenty patients with disseminated non-Hodgkin's lymphoma who failed conventional combination chemotherapy were treated with high-dose chemoradiotherapy and marrow transplantation from an HLA-identical sibling. Four patients remain alive in complete remissi ... Full text Link to item Cite

Chimeras - no longer a myth

Journal Article Immunology Today · January 1, 1983 Since its first successful application less than 15 years ago, allogeneic marrow transplantation has been used with continuously improving results for the treatment of severe aplastic anemia, leukemia and congenital immunodeficiency syndromes. With this ba ... Full text Cite

The predictive value of elevated labial saliva sodium concentration: its relation to labial gland pathology in bone marrow transplant recipients.

Journal Article Hum Pathol · January 1983 Labial minor gland salivary flow rate and sodium concentration were analyzed in relation to 1) histologic findings in labial biopsy specimens and 2) the occurrence of chronic graft-versus-host disease (GVHD) in patients who received bone marrow transplants ... Full text Link to item Cite

Gynecologic manifestations of chronic graft-versus-host disease.

Journal Article Obstet Gynecol · October 1982 Gynecologic manifestations of the clinicopathologic syndrome known as graft-versus-host disease seen in 5 patients treated with allogeneic bone transplantation are presented. The clinical symptoms and significant problems found in association with graft-ve ... Link to item Cite

Treatment of chronic granulocytic leukaemia in chronic phase by allogeneic marrow transplantation.

Journal Article Lancet · September 18, 1982 Ten patients with chronic granulocytic leukaemia in the chronic phase have been treated with chemoradiotherapy followed by transplantation of bone marrow from HLA-identical siblings. Engraftment was achieved in all patients, and Philadelphia chromosome dis ... Full text Link to item Cite

Analysis of late infections after human bone marrow transplantation: role of genotypic nonidentity between marrow donor and recipient and of nonspecific suppressor cells in patients with chronic graft-versus-host disease.

Journal Article Blood · September 1982 Infections occurring 6 mo or later after bone marrow transplantation for severe aplastic anemia or hematologic malignancy were analyzed in 98 long-term survivors. Varicella-zoster (VZ) infections were analyzed separately from all other infections. The fact ... Link to item Cite

Immediate and delayed neurotoxicity after mechlorethamine preparation for bone marrow transplantation.

Journal Article Ann Intern Med · August 1982 Twenty-four patients, including two with aplastic anemia and 22 with malignancy, underwent marrow transplantation after preparation with mechlorethamine, 0.3 to 2.0 mg/kg body weight. Fourteen of the 21 neurologically evaluable recipients developed immedia ... Full text Link to item Cite

Marrow transplantation for thalassaemia.

Journal Article Lancet · July 31, 1982 Full text Link to item Cite

Low serum thymic hormone levels in patients with chronic graft-versus-host disease.

Journal Article Blood · May 1982 We tested the hypothesis that chronic graft-versus-host disease (GVHD) is due to inadequate thymic function by examining pretransplant serum levels of facteur thymique serique (FTS). Four of five patients with no detectable FTS activity developed chronic G ... Link to item Cite

Marrow transplantation with or without donor buffy coat cells for 65 transfused aplastic anemia patients.

Journal Article Blood · February 1982 Sixty-five multiply transfused patients with severe aplastic anemia were given cyclophosphamide followed by grafts anemia were given cyclophosphamide followed by grafts from HLA-identical siblings. The effect of the administration of viable donor buffy coa ... Link to item Cite

Allogeneic marrow transplantation for acute leukemia in relapse.

Journal Article Leuk Res · 1982 The results of allogeneic marrow transplantation in 75 patients with acute lymphoblastic leukemia and 63 patients with acute non-lymphoblastic leukemia in relapse are reviewed. The effects of various chemotherapeutic regimens added to the basic regimen of ... Full text Link to item Cite

Allogeneic marrow transplantation for acute lymphoblastic leukemia in remission using fractionated total body irradiation.

Journal Article Leuk Res · 1982 Twelve patients with acute lymphoblastic leukemia in second to fourth remission received allogeneic marrow transplants following preparation with cyclophosphamide, 120 mg/kg and 1400 rad of fractionated total body irradiation. Two patients died of intersti ... Full text Link to item Cite

Allogeneic marrow transplantation for patients with acute non-lymphoblastic leukemia in second remission.

Journal Article Leuk Res · 1982 Twenty-four patients with acute non-lymphoblastic leukemia (ANL) in second remission were transplanted from HLA-matched siblings. Twelve patients died of non-leukemic causes and four of recurrent leukemia. One patient is alive after relapse and seven patie ... Full text Link to item Cite

Allogeneic marrow transplantation for acute non-lymphoblastic leukemia in relapse using fractionated total body irradiation.

Journal Article Leuk Res · 1982 Twenty-three patients with acute non-lymphoblastic leukemia in relapse were treated with cyclophosphamide, fractionated total body irradiation (200 rad/day for six days) and allogeneic marrow transplantation. Six patients are alive in remission 756-1306 da ... Full text Link to item Cite

Allogeneic marrow transplantation using fractionated total body irradiation in patients with acute lymphoblastic leukemia in relapse.

Journal Article Leuk Res · 1982 Six fractionated total body irradiation (TBI) regimens given over 2-7 days to a total midline dose of between 1200 and 1750 rads were evaluated in 41 patients with acute lymphoblastic leukemia in relapse. Cyclophosphamide 120 mg/kg was given prior to TBI i ... Full text Link to item Cite

Recovery of antibody production in human allogeneic marrow graft recipients: influence of time posttransplantation, the presence or absence of chronic graft-versus-host disease, and antithymocyte globulin treatment.

Journal Article Blood · August 1981 One-hundred fifty-three recipients of HLA-identical sibling marrow transplants for aplastic anemia or hematologic malignancy were injected with bacteriophage phi X174 (phage), pneumococcal polysaccharide antigen (PPA), or keyhole limpet hemocyanin (KLH). A ... Link to item Cite

Esophageal abnormalities in chronic graft-versus-host disease in humans.

Journal Article Gastroenterology · May 1981 Disabling esophageal symptoms ((dysphagia, painful swallowing, and severe restrosternal pain) developed in 8 of 63 patients with chronic graft-versus-host disease after allogeneic bone marrow transplantation. At endoscopy 7 patients had characteristic desq ... Link to item Cite

Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression.

Journal Article Blood · February 1981 Fifty-two of 175 (30%) survivors of allogeneic marrow transplantation developed chronic graft-versus-hose diseases (GVHD). Five with limited chronic GVHD had an indolent clinical course with involvement of only the skin and liver. Forty-seven with extensiv ... Link to item Cite

Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients.

Journal Article Am J Med · August 1980 This study of chronic graft-versus-host disease (GVHD) describes the clinical, pathologic and laboratory features, and the causes of morbidity and mortality in 20 patients who received allogeneic marrow transplants from HLA identical sibling donors. Chroni ... Full text Link to item Cite

Combined modality therapy for advanced, diffuse lymphocytic and histiocytic lymphomas.

Journal Article Cancer · October 1978 Forty-six previously untreated patients with advanced aggressive non-Hodgkin's (34 poorly differentiated and mixed diffuse, 8 histiocytic and 4 undifferentiated) were treated with a 3 phase combined modality program employing cyclophosphamide (C), hydroxyl ... Full text Link to item Cite

Disseminated Nocardia caviae with positive blood cultures.

Journal Article Arch Intern Med · July 1978 Disseminated Nocardia caviae infection with multiple positive blood cultures occurred in a bone marrow transplant recipient. Positive blood cultures are unusual in disseminated Nocardia infections and N caviea is an unusual species of Nocardia to cause inf ... Link to item Cite

Chronic cutaneous graft-versus-host disease in man.

Journal Article Am J Pathol · June 1978 This clinicopathologic study of patients with chronic graft-versus-host disease (GVHD) after allogeneic marrow transplantation emphasizes the most prominent feature of the syndrome, the cutaneous aspects, and describes the ophthalmic-oral sicca syndrome wi ... Link to item Cite